NOVEL THIAZOLOPYRIMIDINE COMPOUNDS

Abstract: The invention provides certain thiazolopyrimidine compounds of general formula (I), processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Description: NOVEL THIAZOLOPYRIMIDINE COMPOUNDS The present invention relates to certain thiazolopyrimidine compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy. The compound 2,7-diamino-5-methylmercapto-thiazolo[4,5-^pyrimidine is known from J. Amer. Chem. Soc, 73, 4226 - 4227 (1951). Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C) and Cys-Cys (C-C) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity. The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2). The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 α and 1 β (MIP- 1 α and MIP- 1 β). Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above. In accordance with the present invention, there is therefore provided a compound of general formula wherein R 1 represents a hydrogen atom, or a group -NR 3 R 4 ; 3 4 R and R each independently represent a hydrogen atom, or a 4-piperidinyl, C3-C6 cycloalkyl or -C8 alkyl group, which latter two groups may be optionally substituted by one or more substituent groups independently selected from halogen atoms and -NR R , -CONR 5 R 6 , -OR 7 , -COOR 7 , -NR 8 COR 9 , -SR 10 , -SO 2 R 10 , -SO 2 NR 5 R 6 , -NR 8 SO 2 R 9 , morpholinyl, -C4 alkyl, C3-C6 cycloalkyl, tetrahydrofuranyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, -NR R , -CONR R , -OR 7 , -NR 8 COR 9 , -SO 2 NR 5 R 6 , -NR 8 SO 2 R 9 , Cι-C 6 alkyl and trifluoromethyl groups, 3 4 - or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one or more substituent groups independently selected from -NR 5 R 6 , -CONR 5 R 6 , -OR 7 , -COOR 10 , -NR 8 COR 9 , and Cι-C 6 alkyl optionally substituted by one or more substituents independently selected from halogen atoms and -NR H R 12 and -OR 7 groups; 13 14 X represents a group -OH or -NR R ; 13 14 R and R each independently represent a hydrogen atom, a 4-piperidinyl group optionally substituted by a C1-C4 alkylphenyl substituent group, or a C3-C7 carbocyclic, C1-C8 alkyl, C 2 -C6 alkenyl or C 2 -Cg alkynyl group, which latter four groups may be optionally substituted by one or more substituent groups independently selected from halogen atoms and -NR 5 R 6 , -CONR 5 R 6 , -OR 7 , -COOR 7 , -NR 8 COR 9 , -SR 10 , -SO 2 R 10 , -SO 2 NR 5 R 6 , -NR 8 SO 2 R 9 , morpholinyl, C r C 4 alkyl, C 3 -C 6 cycloalkyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, -NR 5 R 6 , -CONR 5 R 6 , -OR 7 , -NR 8 COR 9 , -SO 2 NR 5 R 6 , NR 8 SO 2 R 9 , Cι-C 6 alkyl and trifluoromethyl groups, 13 14 or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one or more substituent groups independently selected from -NR R , -CONR 5 R 6 , -OR 7 , -COOR 7 , -NR 8 COR 9 , and Cι-C 6 alkyl optionally substituted by one 11 12 or more substituents independently selected from halogen atoms and phenyl, -NR R 7 and -OR groups; 2 R represents a C1 -0 alkyl or C 2 -Cg alkenyl group optionally substituted by a phenyl or phenoxy group, wherein the phenyl or phenoxy group may itself be optionally substituted by one or more substituents independently selected from halogen atoms and nitro, Cι-C 6 alkyl, trifluoromethyl, -OR 7 , -C(O)R 7 , -SR 10 , -NR 15 R 16 and phenyl groups; R and R each independently represent a hydrogen atom or a Ci-Cg alkyl or phenyl group, each of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, -OR and -NR R , or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system optionally comprising a further heteroatom selected from oxygen and nitrogen atoms, which ring system may be optionally substituted by one or more substituent groups independently selected from phenyl, -OR 17 -COOR 17 , -NR 15 R 16 , -CONR 15 R 16 , -NR 15 COR 16 , -SONR 15 R 16 , and C.-C 6 alkyl optionally substituted by one or more substituents independently selected from halogen atoms and -NR R and -OR groups; 7 9 R and R each independently represent a hydrogen atom or a C j -Cό, particularly C1-C4, alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) or phenyl group, each of which may be optionally substituted by one or more (e.g. one, two, three or four) substituent groups independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine), phenyl, -OR and -NR R ; and , r ,8 ., 10 „ 11 n 12 _ 15 „ 16 . „ 17 . . , each of R , R , R , R , R , R and R independently represents a hydrogen atom or a C1-C6, particularly C1-C4, alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) or 1 2 phenyl group; with the proviso that when R and X both represent -NH 2 , then R does not represent a methyl group; or a pharmaceutically acceptable salt or solvate thereof. In the context of the present specification, unless otherwise indicated, an alkyl or alkenyl group or an alkyl or alkenyl moiety in a substituent group may be linear or branched. Where a substituent in an alkenyl group is a phenoxy group, the phenoxy group is not attached to an unsaturated carbon atom. A carbocyclic group is a saturated hydrocarbyl group that may be monocyclic or polycyclic (e.g. bicyclic). Similarly, a saturated heterocyclic ring system may be monocyclic or polycyclic (e.g. bicyclic). 1 3 4 In formula (I) above, the group R represents a hydrogen atom, or a group -NR R . Particularly advantageous compounds of formula (I) are those in which R represents a 3 4 group -NR R . 3 4 Preferably, R and R each independently represent a hydrogen atom, or a 4-piperidinyl, C3-C6 cycloalkyl (i.e. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) or Cι-Cs, particularly Ci-Cβ, alkyl group (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl or octyl), which latter two groups may be optionally substituted by one, two, three or four substituent groups independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and -NR R , -CONR R , -OR 7 , -COOR 7 , -NR 8 COR 9 , -SR 10 , -SO 2 R 10 , -SO 2 NR 5 R 6 , -NR 8 SO 2 R 9 , morpholinyl, C1-C4 alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl or t-butyl), C3-C6 cycloalkyl (i.e. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), tetrahydrofuranyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one, two, three or four substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and cyano, nitro, -NR R , -CONR R , -OR , -NR 8 COR 9 , -SO 2 NR 5 R 6 , -NR 8 SO 2 R 9 , - , particularly C.-C4, alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) and trifluoromethyl groups, 3 4 or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one, two or three substituent groups independently selected from -NR 5 R 6 , -CONR 5 R 6 , -OR 7 , -COOR 10 , -NR 8 COR 9 , and Cι-C 6 , particularly C1-C4, alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) optionally substituted by one, two or three substituents independently selected from halogen atoms (e.g. fluorine, 11 12 7 chlorine, bromine or iodine) and -NR R and -OR groups. 3 4 Particularly advantageous compounds of formula (I) are those in which R and R each independently represent a hydrogen atom, or a -Cg alkyl group substituted by a -CONR R or imidazolyl (e.g. lH-imidazol-4-yl) group. 2 Preferably, R represents a Cι-C 6 alkyl or C 2 -C 6 alkenyl group optionally substituted by a phenyl or phenoxy group, wherein the phenyl or phenoxy group may itself be optionally substituted by one, two, three or four substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and nitro, C j -Cg, particularly -C4, alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl), trifluoromethyl, -OR 7 , -C(O)R 7 , -SR , -NR R and phenyl groups. 2 Particularly advantageous compounds of formula (I) are those in which R represents a Cι -C6 alkyl group optionally substituted by a phenyl, halophenyl (e.g. 2,3-difluorophenyl) 7 or -OR (e.g. phenoxy) group. Preferably, R and R each independently represent a hydrogen atom or a Cι -C , particularly -C4, alkyl or phenyl group, each of which may be optionally substituted by one, two, three or four substituent groups independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine), phenyl, -OR and -NR R , or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system optionally comprising a further heteroatom selected from oxygen and nitrogen atoms (e.g. one or two oxygen and/or nitrogen atoms), which ring system may be optionally substituted by one, two or three substituent groups independently selected from phenyl, -OR 17 , -COOR 17 , -NR 15 R 16 , -CONR 15 R 16 , -NR 15 COR 16 , -SONR 15 R 16 , and Cι-C 6 , particularly C1-C4, alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) optionally substituted by one, two or three substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and -NR R and -OR groups. 13 14 Preferably, R and R each independently represent a hydrogen atom, a 4-piperidinyl group optionally substituted by a C1-C4 alkylphenyl substituent group, or a C3-C7 carbocyclic, Ci-Cs, particularly Ci-Cό, alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl or octyl), C 2 -C6 alkenyl (ethenyl, propenyl, butenyl, pentenyl or hexenyl) or -Cg alkynyl (ethynyl, propynyl, butynyl, pentynyl or hexynyl) group, which latter four groups may be optionally substituted by one, two, three or four substituent groups independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and -NR 5 R 6 , -CONR 5 R 6 , -OR 7 , -COOR 7 , -NR 8 COR 9 , -SR 10 -SO 2 R 10 , -SO 2 NR 5 R 6 , -NR 8 SO 2 R 9 , morpholinyl, C,-C 4 alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl or t-butyl), C3-C6 cycloalkyl (i.e. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one, two, three or four substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine) and cyano, nitro, -NR R , -CONR 5 R 6 , -OR 7 , -NR 8 COR 9 , -SO 2 NR 5 R 6 , NR 8 SO 2 R 9 , C,-C 6 , particularly C1-C4, alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) and trifluoromethyl groups, 13 14 or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one, two or three substituent groups independently selected from -NR R , -CONR 5 R 6 , -OR 7 , -COOR 7 , -NR 8 COR 9 , and C.- , particularly Cι -C 4 , alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) optionally substituted by one, two or three substituents independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or 11 12 7 iodine) and phenyl, -NR R and -OR groups; Particularly advantageous compounds of formula (I) are those in which one of R 13 and R 14 13 14 represents a hydrogen atom and the other of R and R represents a C 1 -Cg alkyl group substituted by an -OR 7 group, e.g. -CH(CH 2 CH 3 )CH 2 OH, -C(CH 3 ) 2 CH 2 OH or CH(CH 2 CH(CH 3 ) 2 )CH 2 OH. Particularly preferred compounds of the invention include: (2R)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-<i]pyrimidin-7-yl]amino]-l-butanol, (S)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-(i]pyrimidin-7-yl]amino]-l -butanol, 2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-6Tlpyrimidin-7(4H)-one, 5-[[(3-Phenoxyphenyl)methyl]thio]thiazolo[4,5-ύT|pyrimidin-7(4H)-one, 2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-<f]pyrimidin-7(4H)-one, (±)-2-[[2-Amino-5-(pentylthio)thiazolo[4,5-ύTIpyrimidin-7-yl]amino]-l-butanol, 2-[[2-Amino-5-(pentylthio)thiazolo[4,5-< |pyrimidin-7-yl]amino]ethanol, 5-(Pentylthio)thiazolo[4,5- ]pyrimidin-7(4H)-one, 2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-c(Ipyrimidin-7(4H)-one, 2-Amino-5-(pentylthio)thiazolo[4,5-^pyrimidin-7(4H)-one, 2-[[3-(Dimethylamino)propyl]amino]-5-(pentylthio)thiazolo[4,5-i]pyrimidin-7(4H)-one, 2-[[2-(Diethylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-i]pyrimidin-7(4H)-one, 2-[[2-(Dimethylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-<i]pyrimidin-7(4H)-one, 2-[(3-Ηydroxypropyl)amino]-5-(pentylthio)thiazolo[4,5--/]pyrimidin-7(4H)-one, 2-[[2-(Acetylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-cTlpyrimidin-7(4H)-one, (±)-2-[(2,3-Dihydoxypropyl)amino]-5-(pentylthio)thiazolo[4,5-< Ipyrimidin-7(4H)-one, 2-[[2-(4-Moφholinyl)ethyl]amino]-5-(pentylthio)thiazolo[4,5- ]pyrimidin-7(4H)-one, 2-[(2-Methoxyethyl)amino]-5-(pentylthio)thiazolo[4,5- ]pyrimidin-7(4H)-one, 2-[(l-Methylethyl)amino]-5-(pentylthio)thiazolo[4,5- ]pyrimidin-7(4H)-one, 2-(Cyclopropylamino)-5-(pentylthio)thiazolo[4,5-- Jpyrimidin-7(4H)-one, (±)-2-[(2-Ηydoxypropyl)amino]-5-(pentylthio)thiazolo[4,5-<f]pyrimidin-7(4H)-one, 2-[[2-(2-Ηydroxyethoxy)ethyl]amino]-5-(pentylthio)thiazolo[4,5-<i]pyrimidin-7(4H)-one, 2-[(2-Ηydroxy-2-methylpropyl)amino]-5-(pentylthio)thiazolo[4,5-(f]pyrimidin-7(4H)-one, 2-[(2-Ηydroxyethyl)amino]-5-(pentylthio)thiazolo[4,5-cT|pyrimidin-7(4H)-one, (2S,3R)-3-Ηydroxy-2-[(7-oxo-5-(pentylthio)-4H-thiazolo[4,5-^]pyrimidin-2-yl]- amino)butanamide, N 7 -[3-(Dimethylamino)propyl]-5-(pentylthio)thiazolo[4,5-rf]pyrimidine-2,7-diamine, N 7 -[2-(Diethylamino)ethyl]-5-(pentylthio)thiazolo[4,5-ύTlpyrimidine-2,7-diamine, N 7 -[2-(Dimethylamino)ethyl]-5-(pentylthio)thiazolo[4,5-<i]pyrimidine-2,7-diamine, 3-[(2-Amino-5-(pentylthio)thiazolo[4,5- ]pyrimidin-7-yl)amino]-l-propanol, N 7 -Cyclohexyl-5-(pentylthio)thiazolo[4,5-i]pyrimidine-2,7-diamine, (±)-3-[(2-Amino-5-((phenylmethyl)thio)thiazolo[4,5-<i]pyrimidin-7-yl)amino]- 1 ,2- propanediol, N 7 -(2-Methoxyethyl)-5-(pentylthio)thiazolo[4,5- ]pyrimidine-2,7-diamine, 5-(Pentylthio)-N 7 -proρylthiazolo[4,5-^pyrimidine-2,7-diamine, N 7 -Cyclopentyl-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine, N 7 -Cyclopropyl-5-(pentylthio)thiazolo[4,5-t/]pyrimidine-2,7-diamine, N 7 -(2-Methylpropyl)-5-(pentylthio)thiazolo[4,5--i]pyrimidine-2,7-diamine, (±)-l-[(2-Amino-5-(pentylthio)thiazolo[4,5-( ]pyrimidin-7-yl)amino]-2-propanol, (exo)-N 7 -Bicyclo[2.2.1]hept-2-yl-5-(pentylthio)thiazolo[4,5-<i]pyrimidine-2,7-diamine, 2-[2-[[2-Amino-5-(pentylthio)thiazolo[4,5- ]pyrimidin-7-yl]amino]ethoxy]ethanol, (±)-N 7 -(2-Methylbutyl)-5-(pentylthio)thiazolo[4,5-rf]pyrimidine-2,7-diamine, l-[[2-Amino-5-(pentylthio)thiazolo[4,5-<i]pyrimidin-7-yl]amino]-2-methyl-2-propanol, N 7 -[(2-Aminophenyl)methyl]-5-(pentylthio)thiazolo[4,5--i]pyrimidine-2,7-diamine, 2-Amino-5-[(2-phenoxyethyl)thio]thiazolo[4,5--i]pyrimidin-7(4H)-one, (E)-2-Amino-5-[(3-phenyl-2-propenyl)thio]thiazolo[4,5-^]pyrimidin-7(4H)-one, 2-Amino-5-[[3-[2,4-bis(l,l-dimethylethyl)phenoxy]propyl]thio]thiazolo[4,5-cT|pyrimidin- 7(4H)-one, 2-Amino-5-[[[(4-trifluoromethyl)phenyl]methyl]thio]thiazolo[4,5- ]pyrimidin-7(4H)-one, 2-Amino-5-[[(3,5-dichlorophenyl)methyl]thio]thiazolo[4,5-^T]pyrimidin-7(4H)-one, 2-Amino-5-[[(2,4-dichlorophenyl)methyl]thio]thiazolo[4,5-^]pyrimidin-7(4H)-one, 2-Amino-5-[[(3,4-dichlorophenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7(4H)-one, 2-Amino-5-[[(3,5-dibromophenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7(4H)-one, 2-Amino-5-[[(2-nitrophenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7(4H)-one, 2-Amino-5-[[(2-fluorophenyl)methyl]thio]thiazolo[4,5-ύf]pyrimidin-7(4H)-one, 2-Amino-5-[[(2-iodophenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7(4H)-one, 2-Amino-5-[[(3-chlorophenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7(4H)-one, 2-Amino-5-[[(2-chlorophenyl)methyl]thio]thiazolo[4,5-(i]pyrimidin-7(4H)-one, 2-Amino-5-[[(4-chloro-2-nitrophenyl)methyl]thio]thiazolo[4,5- < i]pyrimidin-7(4H)-one, 2-Amino-5-[[(3-chloro-4-methoxyphenyl)methyl]thio]thiazolo[4,5-β pyrimidin-7(4H)-one, 2-Amino-5-[[(2,3-dichlorophenyl)methyl]thio]thiazolo[4,5-< ]pyrimidin-7(4H)-one, 2-Amino-5-[[(3,5-difluorophenyl)methyl]thio]thiazolo[4,5-ύTlpyrimidin-7(4H)-one, 2-Amino-5-[[[(2,4-bis(trifluoromethyl)phenyl]methyl]thio]thiazolo[4,5-( lpyrimidin-7(4H)- one, 2-Amino-5-[[(2-bromophenyl)methyl]thio]thiazolo[4,5-£f|pyrimidin-7(4H)-one, 2-Amino-5-[[(2,3,4-trifluorophenyl)methyl]thio]thiazolo[4,5-cr|pyrimidin-7(4H)-one, 2-Amino-5-[[(3-bromophenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7(4H)-one, 2-Amino-5-[[(2-fluoro-3-methylphenyl)methyl]thio]thiazolo[4,5-cT]pyrimidin-7(4H)-one, 3-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]-2,2-dimethyl-l- propanol, (±)-α-[[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-cQpyrimidin-7- yl]amino]methyl]benzenemethanol, (R)-β-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]benzenepropanol, 2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]ethanol, (2R)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]4- methylpentanol, (±)-l-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-cT]pyrimidin-7-yl]amino]-2-propanol, (±)-β-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-c?]pyrimidin-7-yl]amino]-4- chlorobenzenepropanol, (±)-3-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-cTIpyrimidin-7-yl]amino]-l,2- propanediol, 2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7-yl]propylamino]ethanol, (±)-l-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5--/]pyrimidin-7-yl]-3-pyrrolidinol, (±)-l-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-< lpyrimidin-7-yl]-3-piperidinol, l-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-<i]pyrimidin-7-yl]-4-piperidinol, 3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-i]pyrimidin-7-yl]amino]-2,2- dimethyl- 1 -prdpanol, (±)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]- 1 -butanol, (±)-α-[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-<f]pyrimidin-7-yl]- amino]methyl]benzenemethanol, 4-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]-l- butanol, 6-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7-yl]amino]-l- hexanol, 4-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-. ]pyrimidin-7-yl]- amino]cyclohexanol, (R)-β-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-- |pyrimidin-7-yl]- amino]benzenepropanol, ( ±)-2-[[2-Amino-5-[[(3-phenoxyρhenyl)methyl]thio]thiazolo[4,5-ώflpyrimidin-7-yl]amino]- 1-propanol, 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-< ipyrimidin-7-yl]- amino]ethanol, (2R)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-- lpyrimidin-7-yl]- amino]-4-methylpentanol, (±)-l-Amino-3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-^]pyrimidin-7- yl]amino]-2-propanol, (±)-l-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]- 2-propanol, 2-[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-^pyrimidin-7- yl]amino]methyl]-2-ethyl- 1 ,3-propanediol, (±)-β-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-<f]pyrimidin-7-yl]amino]- 4-chlorobenzenepropanol, (±)-3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-ύf]pyrimidin-7-yl]amino]- 1,2-propanediol, 2-[[2-[[2-Ami ή o-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-ύf|pyrimidin-7- yl]amino]ethyl]amino]ethanol, 3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-f]pyrimidin-7-yl]amino]-l- propanol, (±)-α-[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5--i]pyrimidin-7- yl]amino]methyl]-3,4-dichlorobenzenepropanol, l-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7-yl]amino]-2- methyl-2-propanol, 2-[2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-< ]pyrimidin-7- yl]amino]ethoxy]ethanol, 5-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]-l- pentanol, (2S)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]-4-(methylthio)-l -butanol, 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7- yl]butylamino] ethanol , 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-< ]pyrimidin-7- yl]propylamino]ethanol, 2,2'-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-ύT|pyrimidin-7- yl]imino]bisethanol, 2-[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5--i]pyrimidin-7-yl]-(2- hydroxyethyl)amino]methyl]phenol, 3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-ύT]pyrimidin-7-yl]-(2- hydroxyethyl)amino]- 1 -propanol, (±)-l-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazoIo[4,5-ώT|pyrimidin-7-yl]-3- pyrrolidinol, (tr n^)-l-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-(i]pyrimidin-7-yl]-4- hydroxy-L-proline phenylmethyl ester, (±)-l-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5--i]pyrimidin-7-yl]-3- piperidinemethanol, (±)-l-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7-yl]-3- piperidinol, (2S)-l-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-cTjpyrimidin-7-yl]-2- pyrrolidinemethanol , l-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7-yl]-4- piperidinol, (2R)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7- yl]amino]- 1 -butanol, (2S)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-(i]pyrimidin-7- yl]amino]-l -butanol, (2R)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-i]pyrimidin-7- yl]amino]- 1 -butanol, 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-< lpyrimidin-7-yl]amino]-l,3- propanediol, 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2- methyl-1-propanol, 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]-2- methyl-1-propanol, l-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5--fjpyrimidin-7-yl]amino]-2- methyl -2-propanol, 5-[[(2,3-Difluorophenyl)methyl]thio]-N 7 -(2-fluoroethyl)thiazolo[4,5-cT|pyrimidine-2,7- diamine, ( R-tran^) 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7- yl]amino]-cycloρentanol, ( S-tra«J') 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-ώf]pyrimidin-7- yl]amino]-cyclopentanol, 2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-7-yl]amino]-2-methyl-l- propanol, 2-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-<i]pyrimidin-7- yl] amino] -1-propanol, 2-[[2-[[5-[[(2,3-Difluoroρhenyl)methyl]thio]-2-[(phenylmethyl)amino]thiazolo[4,5- ]pyrimidin-7-yl] amino] -2-methyl- 1 -propanol, 5-[[(2,3-Difluorophenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7(4H)-one, (±)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-.i]pyrimidin-7- yl]amino]-l -butanol, (lS,2S)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]-cyclohexanol, (±)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5- Ipyrimidin-7- y 1 ] amino] - 1 -propanol , 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]-l- ethanol, (2R)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5--i]pyrimidin-7- yl]amino]-4-methyl-l-pentanol, (±)-l-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-< ]pyrimidin-7- yl]amino]-2-propanol, 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7-yl]amino]-2- methyl- 1 ,3-propanediol, l-[[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-cTjpyrimidin-7- yl]amino]methyl]-cyclohexanol, (2R)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]-l-butanol, 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-cripyrimidin-7-yl]-(2- aminoethyl)amino]- 1 -ethanol, 2-[2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-( lpyrimidin-7- yl]amino]ethoxy]-l-ethanol, ( S)- -[( IR)- 1 -[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin- 7-yl]methylamino]ethyl]-benzenemethanol, l-[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5--i]pyrimidin-7-yl]-4- piperidinol, 5-[[(2,3-Difluόrophenyl)methyl]thio]-N 7 -ethyl-thiazolo[4,5-(i]pyrimidine-2,7-diamine, 5-[[(2,3-Difluorophenyl)methyl]thio]-N 7 -(2-propenyl)-thiazolo[4,5- ]pyrimidine-2,7- diamine, (lS,2S)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7- yl] amino] - 1 -phenyl- 1 ,3-propanediol , 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]- 1,3-propanediol, 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-cTlpyrimidin-7-yl]amino]-l- ethanol, (±)-5-[[(2,3-Difluorophenyl)methyl]thio]-N 7 -(2-methoxy-l-methylethyl)-thiazolo[4,5- i |pyrimidine-2,7-diamine, N 7 -Cyclopropyl-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-<i]pyrimidine-2,7- diamine, (±)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-ύ0pyrimidin-7- yl] amino] - 1 -propanol , 4-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-< ]pyrimidin-7-yl]amino]-l- butanol, 5-[[(2,3-Difluorophenyl)methyl]thio]-N 7 -[2-(lH-imidazol-4-yl)ethyl]-thiazolo[4,5- d]pyrimidine-2,7-diamine, (±)-N-[5-[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-l,l- dimethylethyl)amino]thiazolo[4,5-JJpyrimidin-2-yl]-serine, methyl ester, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(l-methylethyl)amino]thiazolo[4,5- d] pyrimidin-7-yl] amino] -2-methyl- 1 -propanol , 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-(ethylamino)thiazolo[4,5- ]pyrimidin-7- yl] amino] -2-methyl - 1 -propanol , 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(lH-indol-3-yl)ethyl]amino]thiazolo[4,5- <i]pyrimidin-7-yl]amino]-2-methyl-l-propanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(l-naphthalenylmethyl)amino]thiazolo[4,5- d] pyrimidin-7-yl] amino] -2-methyl- 1 -propanol , 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(l,2-diphenylethyl)amino]thiazolo[4,5- ]pyrimidin-7-yl]amino]-2-methyl-l -propanol, 2-[[5-[[(2,3-Difluoroρhenyl)methyl]thio]-2-[(2,2,2-trifluoroethyl)amino]thiazolo[4,5- cTIpyrimidin-7-yl]amino]-2-methyl-l -propanol, 2-[[5-[[(2,3-Difluoroρhenyl)methyl]thio]-2-[[(3,4,5- trimethoxyphenyl)methyl]amino]thiazolo[4,5-cTipyrimidin-7-yl]amino]-2-methyl-l- propanol, 2-[[5-[[(2,3-Difluoroρhenyl)methyl]thio]-2-[(l,l-dimethylethyl)amino]thiazolo[4,5- c/]pyrimidin-7-yl]amino]-2-methyl- 1 -propanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5- d]pyrimidin-7-yl]amino]-2-methyl- 1 -propanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(4-methylcyclohexyl)amino]thiazolo[4,5- ]pyrimidin-7-yl] amino] -2-methyl- 1 -propanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy- 1,1- dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-2-yl]amino]-acetamide, 2-[[2-[[2-(4-Aminophenyl)ethyl]amino]-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5- -i]pyrimidin-7-yl] amino] -2-methyl- 1 -propanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5- d]pyrimidin-7-yl]amino]-2-methyl-l -propanol, 2-[[2-(Cyclopropylamino)-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7- yl]amino]-2-methyl- 1 -propanol, (±)-2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy- 1,1- dimethylethyl)amino]thiazolo[4,5-< Ipyrimidin-2-yl]amino]-l-pentanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2- hydroxyethoxy)ethyl]amino]thiazolo[4,5-c pyrimidin-7-yl]amino]-2-methyl-l-propanol, N-[5-[[(2,3-Difluorophenyl)methyl]thio]-6,7-dihydro-7-oxo-thiazolo[4,5-<i]pyrimidin-2- yl]-DL-serine, methyl ester, 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(l-methylethyl)amino]-thiazolo[4,5-rf]pyrimidin- 7(4H)-one, 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(lH-indol-3-yl)ethyl]amino]-thiazolo[4,5- <i]pyrimidin-7(4H)-one, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-6,7-dihydro-7-oxo-thiazolo[4,5-< lpyrimidin-2- yl]amino]-acetamide, 2-[[2-(4-Aminophenyl)ethyl]amino]-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5- <i]pyrimidin-7(4H)-one, 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]-thiazolo[4,5-<i]pyrimidin- 7(4H)-one, 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-hydroxyethoxy)ethyl]amino]-thiazolo[4,5- <fjpyrimidin-7(4H)-one, 2-[[2-(Cyclohexylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-7-yl]amino]-2- methyl- 1 -propanol, 2-[[2-[(l,l-Dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]-2-methyl- 1 -propanol, ^-[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-2-yl]-DL-alanine, methyl ester, 4-[[7-[(2-Hydroxy- 1 , 1 -dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ^pyrimidin-2-yl]amino]-cyclohexanol, 2-Methyl-2-[[2-[(4- P henylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]-l -propanol, 2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5- d]pyrimidin-7-yl]amino]- 1 -propanol, 2-Methyl-2-[[2-[(l-methyle-hyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]- 1 -propanol, 2-[[2-[[2-(4-Aminophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-7- yl]amino]-2-methyl- 1 -propanol, N-[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ethyl ester, (2S)-2-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ^]pyrimidin-2-yl]amino]-4-methyl-pentanamide, 2-Methyl-2-[[2-[(2-phenylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]- 1-propanol, 2-[[2-[[(4-Aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-^pyrimidin-7- yl]amino]-2-methyl- 1 -propanol, 2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5- <i]pyrimidin-7-yl]amino]-l-propanol, 2-[[2-[(2-Fluoroethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-- ]pyrimidin-7-yl]amino]- 2-methyl- 1 -propanol, 2-Methyl-2-[[2-[[(3-nitrophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- cQpyrimidin-7-yl]amino]-l -propanol, (αR)-α-[( 1 S)- 1 -[[7-[(2-Hydroxy- 1 , 1 -dimethylethyl)amino]-5- [(phenylmethyl)thio]thiazolo[4,5-(i]pyrimidin-2-yl]amino]ethyl]-benzenemethanol, 2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[(3,4,5- trimethoxyphenyl)methyl]amino]thiazolo[4,5- ]pyrimidin-7-yl]amino]-l-propanol, 2-Methyl-2-[[2-[(lR-trans)-(2-phenylcyclopropyl)amino]-5- [(phenylmethyl)thio]thiazolo[4,5-i]pyrimidin-7-yl]amino]-l-propanol, 2-[[2-[[2-(lH-Indol-3-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]-2-methyl- 1 -propanol, 2-[[2-[( 1 , 1 -Dimethylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-- lpyrimidin-7- yl]amino]-2-methyl- 1 -propanol, (±)-2-Methyl-2-[[2-[(l-methylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- c?]pyrimidin-7-yl]amino]- 1 -propanol, (±)-2-Methyl-2-[[2-[(l-methylhexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]-l -propanol, 2-[[2-[[(2-Aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-( Ipyrimidin-7- yl]amino]-2-methyl- 1 -propanol, 2-[[7-[(2-Ηydroxy- 1 , 1 -dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- cTlpyrimidin-2-yl]amino]- 1 ,3-propanediol, 2-[[2-[[2-(Ethylthio)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-cT]ρyrimidin-7- yl]amino]-2-methyl-l -propanol, (2S)-2-[[7-[(2-Hydroxy- 1 , 1 -dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-2-yl]amino]-3,3-dimethyl-l-butanol, (αS)-α-[(lR)-l-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5- [(phenylmethyl)thio]thiazolo[4,5--f|pyrimidin-2-yl]amino]-2-methoxyethyl]- benzenemethanol, 2-[[2-(Ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-i]pyrimidin-7-yl]amino]-2-methyl- 1 -propanol, 2-[[2-[[[3-Fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-5- [(phenylmethyl)thio]thiazolo[4,5-cT|pyrimidin-7-yl]amino]-2-methyl-l-propanol, (±)-2-Methyl-2-[[2-[(l-methylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- <i]pyrimidin-7-yl] amino] - 1 -propanol, 2-[[2-[[(4-Methoxyphenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin- 7-yl]amino]-2-methyl-l-propanol, 2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]-2-methyl-l-propanol, 2-[[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d']pyrimidin- 7-yl]amino]-2-methyl-l-propanol, 2-[[2-[(Diphenylmethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-if|pyrimidin-7- yl]amino]-2-methyl-l-propanol, (2S)-2-[[7-[(2-Ηydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- (flpyrimidin-2-yl] amino]- 1 -butanol, 2-[[2-[(2,2-Diethoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5--i]pyrimidin-7- yl] amino] -2-methyl- 1 -propanol, 4-[[7-[(2-Hydroxy- 1 , 1 -dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- cf|pyrimidin-2-yl]amino]-l-butanol, (lS,2S)-2-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- _i]pyrimidin-2-yl]amino]-cyclohexanol, (±)-2-[[2-[(2-Hydroxy-l-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- uf]pyrimidin-7-yl]amino]-2-methyl-l-propanol, 2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(ρhenylmethyl)thio]thiazolo[4,5- ]pyrimidin- 7-yl]amino]-2-methyl- 1 -propanol, (±)-2-[[7-[(2-Hydroxy-l, l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- cf]pyrimidin-2-yl]amino]-l-pentanol, 2-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- - ]pyrimidin-2-yl]amino]-acetamide, (±)-2-[[2-[[l-(4-Fluorophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- J]pyrimidin-7-yl]amino]-2-methyl-propanol, (lR,2S)-2-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- rf]pyrimidin-2-yl]amino]-cyclohexanol, (aS)-a-[(lR)- 1 -[[7-[(2-Hydroxy- 1 , 1 -dimethylethyl)amino]-5- [(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-2-yl]amino]ethyl]-benzenemethanol, (±)-2-[[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-ώ ipyrimidin-7-yl]amino]-l- propanol, (2R)-4-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-if]pyrimidin-7- yl]amino]-l-pentanol, N-[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-(i]pyrimidin-7-yl]-L-serine, ethyl ester, (±)-2-[[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5- ώf|pyrimidin-7-yl]amino]-l -butanol, (±)-2-[[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5- ώf]pyrimidin-7-yl]amino]- 1 -propanol, (2R)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[(tetrahydro-2- furanyl)methyl]amino]thiazolo[4,5-<i]pyrimidin-7-yl]amino]-l-pentanol, N-[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5- ύf]pyrimidin-7-yl]-L-serine, ethyl ester, (±)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- d]pyrimidin-7-yl]amino]-l -propanol, (±)-4-[2-[[7-[[l-(Hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide, (±)-4-[2-[[7-[(2-Hydroxy-l-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- c0pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide, 4- [2- [ [7-[ [( 1 R)- 1 -(Hydroxymethyl)-3-methylbutyl] amino]-5- [(phenylmethyl)thio]thiazolo[4,5-ώ0pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide, (±)-4-[2-[[7-[(2-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-i]pyrimidin-2- yl]amino]ethyl]-benzenesulfonamide, N 7 -Ethyl-N 2 -[2-(lH-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thiothiazolo[4,5- lpyrimidine- 2,7-diamine, N 2 -[2-(lH-Imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]-N 7 -(3-pyridinylmethyl)- thiazolo[4,5-<i]pyrimidine-2,7-diamine, (±)-2-[[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- d]pyrimidin-7-yl]amino]- 1-butanol, (±)-2-[[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- < f]pyrimidin-7-yl]amino]- 1-propanol, (2R)-2-[[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- d]pyrimidin-7-yl] amino] -4-methyl- 1 -pentanol, (±)-l-[[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]-2-propanol, 5-[[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-c?]pyrimidin- 7-yl]amino]-l -pentanol, l-[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-ύ?]pyrimidin- 7-yl]-4-(phenylmethyl)-4-piperidinol, (±)-l-[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- < |pyrimidin-7-yl]-3-piperidinecarboxamide, 2-[Ethyl[2-[[2-(lH-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- i]pyrimidin-7-yl]amino]-l -ethanol, N 2 -[2-(lH-Imidazol-4-yl)ethyl]-N 7 ,N 7 -dimethyl-5-[(phenylmethyl)thio]- thiazolo[4,5- <i]pyrimidine-2,7-diamine, N 7 -[2-(Diethylamino)ethyl]-N 7 -ethyl-N 2 -[2-(lH-imidazol-4-yl)ethyl]-5- [(phenylmethyl)thio]-thiazolo[4,5-<i]pyrirαidine-2,7-diamine, N 2 -(2-Phenoxyethyl)-5-[(phenylmethyl)thio]-N 7 -(3-pyridinylmethyl)-thiazolo[4,5- d]pyrimidine-2,7-diamine, N 2 -(2-Phenoxyethyl)-N 7 -[l-(phenylmethyl)-4-piperidinyl]-5-[(phenylmethyl)thio]- thiazolo[4,5-i]pyrimidine-2,7-diamine, 2-Methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin- 7-yl]amino]- 1-propanol, (±)-2-[[2-[(2-Phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-<i]pyrimidin-7- yl] amino]- 1 -propanol, (±)-4-Methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ύπpyrimidin-7-yl]amino]-l -pentanol, l-[2-[(2-Phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5--fIpyrimidin-7-yl]-4- (phenylmethyl)-4-piperidinol, 2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-ύf]pyrimidin-7-yl]amino]-l- butanol, 2-[[2-(Cycloproρylamino)-5-[(phenylmethyl)thio]thiazolo[4,5--i]pyrimidin-7-yl]amino]- 1 - propanol, (2R)-2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-< lpyrimidin-7- yl]amino]-4-methyl-l-pentanol, N-[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-<i]pyrimidin-7-yl]-L-serine, ethyl ester, (2R)-2-[[2-[[l-(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- -f]pyrimidin-7-yl]amino]-4-methyl- 1 -pentanol, N-[2-[[l-(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl]-L-serine, ethyl ester, (±)-2-[[7-[Cyclohexyl(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- cTlpyrimidin-2-yl]amino]- 1 -pentanol, 2-[2-[[7-(Ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-ύπpyrimidin-2-yl]amino]ethoxy- 1 -ethanol, 2-[2-[[7-[(l-Methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-ύGpyrimidin-2- yl]amino]ethoxy]-l -ethanol, (±)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]-l-butanol, 2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-<i]pyrimidin- 7-yl]amino]-2-methyl-l-propanol, (2R)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]-4-methyl-l -pentanol, 2-[Cyclohexyl-[2-[[2-(2-hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- d]pyrimidin-7-yl] amino] - 1 -ethanol, (±)-2-[[5-[(Phenylmethyl)thio]-2-(4-piperidinylamino)thiazolo[4,5-< ]pyrimidin-7- yl]amino]- 1-propanol, (±)-N-[2-[[7-[[l-(Hydroxymethyl)propyl]amino]-5-[(phenylmethyl ) thio]thiazolo[4,5- <i]pyrimidin-2-yl]amino]ethyl]-acetamide, (±)-N-[2-[[7-[(2-Hydroxy-l-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-2-yl]amino]ethyl]-acetamide, ^-[2-[[7-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-2- yl]amino]ethyl]-acetamide, N-[2-[[7-[[(lR)-l-(Hydroxymethyl)-3-methylbutyl]amino]-5- [(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-2-yl]amino]ethyl]-acetamide, N 7 -(2-Methoxyethyl)-5-[(phenylmethyl)thio]-N 2 -[2-(2-thienyl)ethyl]thiazolo[4,5- <i]pyrimidine-2,7-diamine, N 7 -(2-Ethoxyethyl)-5-[(phenylmethyl)thio]-N 2 -[2-(2-thienyl ) ethyl]thiazolo[4,5- <i]pyrimidine-2,7-diamine, N 7 -(2,2-Dimethylpropyl)-5-[(phenylmethyl)thio]-N 2 -[2-(2-thienyl)ethyl]thiazolo[4,5- <i]pyrimidine-2,7-diamine, (2R)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5- -i]pyrimidin-7-yl]amino]- 1 -pentanol, (±)-l-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-^]pyrimidin-7- yl] amino]- 2-propanol, (±)-2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5- ]pyrimidin-7- yl]amino]- 1-butanol, (±)-2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5- ]pyrimidin-7- yl] amino]- 1-propanol, (2R)-2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- tlpyrimidin-7- yl]amino]-4-methyl- 1 -pentanol, ( ± ) -N,N-Diethyl-l-[2-[(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- -f]pyrimidin-7-yl]-3-piperidinecarboxamide, (2R)-2-[[2-[(3-Hydroxypropyl)amino]-5-[( phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-7- y 1] amino] -4-methyl- 1 -pentanol , (±)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]-l -butanol, (±)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-7- yl]amino]- 1-propanol, 2-[[7-[(2-Hydroxy-l-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5--i]pyrimidin- 2-yl]amino-acetamide, 5 4-[l-[7-[(4-Methylcyclohexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-2- yl]-3-azetidinyl]- 1 -piperazinesulfonamide, 3-[[2-[[2-(4-Morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-^]pyrimidin-7- yl]amino]- 1 -propanol, 2-Methyl-2-[[2-[[2-(4-morρholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- l o ^pyrimidin-7-yl] amino] - 1 -propanol, (±)-2-[[2-[[2-(4-Morρholinyl)ethyl]amino]-5-[(ρhenylmethyl)thio]thiazolo[4,5- <i]pyrimidin-7-yl]amino]- 1-propanol, (2R)-4-Methyl-2-[[2-[[2-(4-moφholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- d]pyrimidin-7-yl]amino]- 1 -pentanol, is 2-[[2-(3,4-Dihydroxyphenyl)ethyl]amino]-5-[(phenylmethyl)thio]-thiazolo[4,5- < ]pyrimidin-7(4H)-one, (±)-2-[(2-Ηydroxy-l-methylethyl)amino]-5-[(phenylmethyl)thio]-thiazolo[4,5--i]pyrimidin- 7(4H)-one, and their pharmaceutically acceptable salts and solvates. 20 According to the invention there is also provided a process for the preparation of a compound of formula (I) which comprises (a) when X represents -OΗ and R is NΗ 2 , heating a compound of general formula 2 25 wherein R is as defined in formula (I); or (b) when X represents -OH and R is NH 2 , reacting a compound of formula 2 1 1 with a compound of general formula (IV), R - L , wherein L represents a leaving group 2 such as a halogen atom (e.g. chlorine) and R is as defined in formula (I); or (c) when X represents -OH or -NR R and R is a hydrogen atom, reacting a corresponding compound of formula (I) in which R is NH 2 , with a diazotizing agent; or 1 3 4 (d) when X represents -OH and R is a group -NR R , reacting a compound of general formula 2 2 wherein L represents a leaving group such as a halogen atom (e.g. bromine) and R is as 3 4 3 defined in formula (I), with a compound of general formula (VI), R R NH, wherein R and 4 R are as defined in formula (I); or 13 14 1 3 4 (e) when X represents -NR R and R represents -NR R , reacting a compound of general formula wherein L represents a leaving group such as a halogen atom (e.g. chlorine) and R , R " 4 and R are as defined in formula (I), with a compound of general formula (VIE), 13 14 13 14 NHR R , wherein R and R are as defined in formula (I); or 13 14 1 3 4 (f) when X represents -NR R and R represents -NR R , reacting a compound of general formula wherein L 4 is a leaving group (e.g. bromine), L 5 is a leaving group (e.g. chlorine) and R is as defined in formula (I), initially with a compound of formula (VI) as defined in (d) above followed by reaction with a compound of formula (VET) as defined in (e) above; and optionally after (a), (b), (c), (d), (e) or (f) forming a pharmaceutically acceptable salt or solvate of the compound of formula (I). Process (a) is conveniently carried out in the presence of a solvent or solvent mixture such as dimethylformamide/water at a temperature in the range from e.g. 50 to 150°C. Process (b) is conveniently carried out in an organic solvent such as tetrahydrofuran or dimethyl sulphoxide/dimethylforma ide mixture, optionally in the presence of a base such as potassium tert-butoxide or diisopropylamide. Process (c) is conveniently carried out in an organic solvent such as tetrahydrofuran. Examples of suitable diazotizing agents to use include tert-butyl nitrite. Process (d) is conveniently carried out in an organic solvent such as tetrahydrofuran, e.g. at a temperature of 50°C for 5 hours. Process (e) is conveniently carried out in an organic solvent such as tetrahydrofuran with heating for a period in the range from 1 day to 3 weeks. Process (f) is conveniently carried out in an organic solvent such as tetrahydrofuran or N-methylpyrrolidine at a temperature between 0° and 130°C, with a reaction time of 1 hour to 3 weeks. Compounds of formula (II) may be readily prepared by reacting a compound of general formula 2 wherein R is as defined abov ree,, wwiitthh ppoottaassssiiuumm tthhiiooccyyaarnate and bromine in dimethylformamide/pyridine. Compounds of formula (X) are suitably prepared by reacting a compound of formula with a compound of formula (IV) as defined above. Compounds of formula (V) may be prepared by reacting a compound of formula (I) in which R is NH2, with a diazotizing agent and a halogenating agent. The reaction is conveniently carried out in an organic solvent such as acetonitrile in the presence of a diazotizing agent such as tert-butyl nitrite and a halogenating agent such as a trimethylsilyl halide. 3 Compounds of formula (VII) in which L is a chlorine atom may be prepared by reacting a compound of formula (I) in which X is -OH with phosphorus oxychloride in dimethylaniline under reflux conditions. 4 5 Compounds of formula (LX) in which L represents a bromine atom and L represents a chlorine atom may be prepared by reacting a compound of formula (I) in which X is -OH aanndd RR iiss NNHH 22 wwiitthh pphhoosspphhoorruuss ooxxyycchhlloorriiddee iinn ddiimmeetthhyyllaanniiline under reflux conditions, followed by reaction with tert-butyl nitrite and bromoform. Compounds of formulae (ET), (IV), (VI), (VET) and (XI) are either commercially available, are well known in the literature or may be prepared easily using known techniques. The compounds of formulae (V), (VE) and (K) are novel intermediates and therefore form a further aspect of the present invention. In formula (V), L 2 is preferably a bromine atom. 3 4 In formula (VE), R and R preferably both represent a hydrogen atom. In formula (LX), L is preferably a bromine atom and L is preferably a chlorine atom. It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups. The protection and deprotection of functional groups is fully described in 'Protective Groups in Organic Chemistry', edited by J. W. F. McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 2nd edition, T. W. Greene & P. G. M. Wuts, Wiley-lnterscience (1991). The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or p-toluenesulphonate. Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention, for example tautomers of general formula where i n R formula wherein R and are as defined in formula (I). Similarly, it will be understood that in the above processes tautomeric forms of the compounds of formulae (E), (ET), (LX) and ( and The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CXCR2) activity, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines. Examples of such conditions/diseases include: (1) (the respiratory tract) obstructive airways diseases including chronic obstructive pulmonary disease (COPD) such as irreversible COPD; asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia; (2) (bone and joints) rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis; (3) (skin) psoriasis, atopical dermatitis, contact dermatitis and other eczmatous dermitides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis; (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinopilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema; (5) (other tissues and systemic disease) multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (ADDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, sezary syndrome and idiopathic thrombocytopenia pupura; (6) (allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease; (7) cancers, especially non-small cell lung cancer (NSCLC) and squamous sarcoma; (8) diseases in which angiogenesis is associated with raised CXCR2 chemokine levels (e.g. NSCLC); and (9) cystic fibrosis, stroke, re-perfusion injury in the heart, brain, peripheral limbs and sepsis. Thus, the present invention provides a compound of formula (I), or a pharmaceutically- acceptable salt or solvate thereof, as hereinbefore defined for use in therapy. In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy. In a still further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial. In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly. The invention still further provides a method of treating a chemokine mediated disease wherein the chemokine binds to a CXCR2 receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined. The invention also provides a method of treating an inflammatory disease, especially psoriasis, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined. For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition. The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier. The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier. The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally. The invention will now be further illustrated by reference to the following examples. In the examples the Nuclear Magnetic Resonance (NMR) spectra were measured on a Varian Unity Inova 300 or 400 MHz spectrometer and the Mass Spectrometry (MS) spectra measured on a Finnigan Mat SSQ7000 or Micromass Platform spectrometer. Where necessary, the reactions were performed under an inert atmosphere of either nitrogen or ® argon. Chromatography was generally performed using Matrex Silica 60 (35-70 micron) ® or Prolabo Silica gel 60 (35-70 micron) suitable for flash silica gel chromatography. High pressure liquid chromatography purification was performed using either a Waters Micromass LCZ with a Waters 600 pump controller, Waters 2487 detector and Gilson FC024 fraction collector or a Waters Delta Prep 4000. The abbreviations m.p. and DMSO used in the examples stand for melting point and dimethyl sulphoxide respectively. Example 1 (2R)-2-[[2-Amino-5-[(phenyImethyI)thio]thiazoIo[4,5-rf]pyrimidin-7-yl]amino]-l- butanol (a) 7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-2-amine 2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-^pyrimidin-7(4H)-one (0.89g) (prepared as described in Example 9), phosphorus oxychloride (12mL) and N,N-dimethylaniline (1.2mL) were heated at reflux for 2 hours. The cooled reaction mixture was poured onto ice and water and stirred for 2 hours. Chromatography on silica eluting with methanol/dichloromethane mixtures gave the sub-title chloride. m.p. 217-218.5°C MS: APCI(-f-ve) 309/11 (M+l) l H ΝMR: δ (DMSO) 4.38 (s,2Η), 7.20-7.48 (m,5H) and 8.95 (br s,2H). (b) (2R)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-7-yl]amino]-l- butanol The chloro compound from step (a) (0.12g) in tetrahydrofuran (3 mL) was treated with (R)-2-amino-l -butanol (0.56g) and the reaction mixture was heated at reflux for 5 days. Dichloromethane and dilute hydrochloric acid were added. The resulting solid was filtered off, washed with water and ether to give the title compound which was obtained containing 0.23 moles of hydrogen chloride and 0.93 moles of water. Yield 0.045g. m.p. 118-121°C MS: APCI(+ve) 362 (M+l) l H NMR: δ (DMSO) 0.83 (t,3H), 1.45 (m,2H), 1.65 (m,2H), 3.39 (m,2H), 4.31 (q,2H), 4.65 (t,lH), 6.91 (d,lH), 7.17-7.44 (m,5H) and 8.00 (s,2H). Example 2 (5)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yI]amino]-l- butanol Prepared by the method of Example 1(b) from the chloro compound of Example 1(a) and (S)-2-amino-l -butanol. Obtained as a solid containing 0.7 moles of hydrogen chloride. mp 204-208°C MS: APCI(+ve) 362 (M+l) l H NMR: δ (DMSO) 0.82 (t,3H), 1.37-1.74 (m,2H), 3.36-3.52 (m,2H), 4.10 (br s,lH), 4.41 (q,2H), 7.20-7.46 (m,5H), 7.63 (br s,lH) and 8.42 (s,2H). Example 3 2-Amino-5-[[(2,3-difluorophenyl)methyI]thio]thiazolo[4,5-rf]pyrimidin-7(4£ - ne a) 2-Amino-5-mercapto-thiazolo[4,5--f]pyrimidin-7(4fl r )-one Aluminium tribromide (IM in CH 2 Br 2 , 15.2ml) was added to a solution of the product of Example 9 (2.0g) in toluene (25ml) and the reaction mixture heated at 60°C for 6 hours. On cooling to room temperature, water (40ml) was added and the resulting solid isolated by filtration then triturated with hot ethanol to afford the sub-title compound (0.8g). MS: (APCI) 201 (M+H + , 100%) b) 2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7(4fl r )-one Potassium t-butoxide solution (0.45mL of IM in tetrahydrofuran) was added to a stirred solution of the product of step a) (0.09g) and 2,3-difluorobenzyl bromide in dimethyl sulphoxide (2mL). After stirring for 3 days, the reaction mixture was poured onto water. The title compound was obtained. Yield 0.065g. m.p. 310-313°C MS: APCI(+ve) 327 (M+l) ! H NMR: δ (DMSO) 4.48 (s,2H), 7.18-7.45 (m,3H), 8.20 (s,2H) and 12.62 (s,lH). Example 4 5-[[(3-Phenoxyphenyl)methyI]thio]thiazolo[4,5-rf]pyrimidin-7(4JΪ)-one 2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7(4H)-one (0.3g) (product of Example 5) was added over 90 minutes to a solution of t-butyl nitrite (0.17mL) in tetrahydrofuran (3mL) at 65°C. After a further 3.5 hours at 65°C, the solvent was evaporated and the residue chromatographed on silica eluting with methanol/dichloromethane mixtures to give the title compound. Yield 0.07 lg. m.p. 197-198°C MS: APCI(+ve) 368 (M+l) Η NMR: δ (DMSO) 4.49 (s,2H), 6.86-7.38 (m,9H), 9.58 (s,lH) and 13.11 (s,lH). Example 5 2-Amino-5-[[(3-phenoxyphenyl)methyI]thio]thiazoIo[4,5-rf]pyrimidin-7(4fl r )-one Prepared by the method of Example 3 using 3-phenoxybenzyl chloride. m.p. 266-269°C MS: APCI(+ve) 383 (M+l) λ H NMR: δ (DMSO) 4.40 (s,2H), 6.81-7.41 (m,9H), 8.15 (s,2H) and 12.55 (s,lH). Example 6 (±)-2-[[2-Amino-5-(pentylthio)thiazolo[4,5-<f|pyrimidin-7-yl]amino]-l-butanoI (a) 7-Chloro-5-(pentylthio)thiazolo[4,5-rf]pyrimidin-2-amine Prepared by the method of Example 1 (a) from 2-amino-5-(pentylthio)thiazolo[4,5- < ]pyrimidin-7(4H)-one (product of Example 10). m.p. 176.5-177.5°C MS: APCI(+ve) 289 (M+l) l HH N NMMRR:: δ δ (DMSO) 0.88 (t,3Η), 1.22-1.42 (m,4H), 1.60-1.74 (m,2H), 3.08 (t,2H) and 8.90 (s,2H). (b) (±)-2-[[2-Amino-5-(pentylthio)thiazoIo[4,5--i]pyrimidin-7-yl]amino]-l-butanol Prepared by the method of Example 1(b) from the chloro compound of Example 6(a) and the appropriate amine. m.p. 151-154°C MS: APCI(+ve) 342 (M+l) ! H NMR: δ (DMSO) 0.82-0.95 (m,6H), 1.22-1.72 (m,8H), 3.04 (m,2H), 3.39-3.56 (m,2H), 4.07 (m,lH), 4.64 (t,lH), 6 88 (d,lH), 7.44 (br s,lH) and 7.96 (s,2H). Example 7 2-[[2-Amino-5-(pentylthio)thiazolo[4,5-rf]pyrimidin-7-yI]amino]ethanol Prepared by the method of Example 6(b). m.p. 192-195°C MS: APCI(+ve) 314 (M+l) l H NMR: δ (DMSO) 0.87 (t,3H), 1.21-1.42 (m,4H), 1.57-1.70 (m,2H), 2.99 (t,2H), 3.37-3.46 (m,2H), 3.46-3.58 (m,2H), 4.71 (t,lH), 7.22 (t,lH) and 7.97 (s,2H). Example 8 5-(Pentylthio)thiazolo[4,5-rf]pyrimidin-7(4ff)-one Prepared by the method of Example 4. m.p. 208-209°C MS : APCI(+ve) 256 (M+ 1 ) ! H NMR: δ (DMSO) 0.88 (t,3H), 1.22-1.44 (m,4H), 1.63-1.75 (m,2H), 3.20 (t,2H), 9.57 (s,lH) and 13.06 (s,lH). Example 9 2-Amino-5-[(phenyImethyl)thio]thiazolo[4,5-rf]pyrimidin-7(4fl -one (a) 6-Amino-2-[(phenyImethyl)thio]-5-thiocyanato-4(lfl r )-pyrimidinone 6-Amino-2-[(phenylmethyl)thio]-4(lH)-pyrimidinone (10.5g) (prepared as described in WO 96/35678) and potassium thiocyanate (25g) in dimethylformamide (200mL) were heated together at 65°C. Pyridine (6.3mL) was added and the solution cooled to 5°C. Bromine (2.2mL) was added slowly and the reaction mixture stirred for 2 hours at 5-10°C. The reaction mixture was poured onto ice and water, stirred for 1 hour and the solid was filtered off. After washing with water and ether a pure sample was obtained after tituration with hot methanol. m.p. 260-262°C MS: APCI(+ve) 291 (M+l) l H NMR: δ (DMSO) 4.38 (s,2Η), 7.21-7.51 (m,5H), 7.70 (br s,2H) and 12.35 (s,lH). (b) 2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-- ]pyrimidin-7(4iH r )-one The product of step (a) (7.35g) was heated at 120°C in dimethylformamide (40mL) and water (lOmL) for 10 hours. After cooling, the resulting solid was filtered off, washed with water, ether and ethyl acetate to give the title compound containing 0.4 moles of dimethylformamide. m.p. -325° MS: APCI(+ve) 291 (M+l) l H NMR: δ (DMSO) 4.41 (s,2H), 7.21-7.50 (m,5H), 8.17 (s,2H) and 12.53 (br s,lH). Example 10 2-Amino-5-(pentylthio)thiazolo[4,5-<f]pyrimidin-7(4β)-one (a) 6-Amino-2-(pentylthio)-5-thiocyanato-4(l T)-pyrimidinone Prepared by the method of Example 9(a). m.p. 260-262°C MS: APCI(+ve) 214 (M+l) l H NMR: δ (DMSO) 0.86 (t,3H), 1.22-1.40 (m,4H), 1.56-1.68 (m,2H), 3.10 (t,2H), 7.58 (br s,2H) and 12.30 (s,lH). (b) 2-Amino-5-(pentylthio)thiazolo[4,5 |pyrimidin-7(4/i f )-one Prepared by the method of Example 9(b). MS: APCI(+ve) 271 (M+l) l H NMR: δ (DMSO) 0.86 (t,3H), 1.24-1.40 (m,4H), 1.58-1.70 (m,2H), 3.12 (t,2H), 8.12 (br s,2H) and 12.49 (s,lH). Example 11 2-Bromo-5-(pentylthio)thiazolo[4,5-rf]pyrimidin-7(4H)-one Trimethylsilyl bromide (0.44mL) was added slowly to a solution at 0°C under nitrogen of t-butyl nitrite (0.42mL) in acetonitrile (2mL). After 30 minute at 0°C, 2-amino-5- (pentylthio)thiazolo[4,5-_i]pyrimidin-7(4H)-one (0.5g) (product of Example 10) was added. The reaction mixture was stirred at room temperature for 16 hours and the solvent was evaporated. Chromatography on silica eluting with dichloromethane/methanol mixtures gave the title bromide. m.p. 189-191°C MS: APCI(+ve) 336/7 (M+l) l H NMR: δ (DMSO) 0.88 (t,3H), 1.26-1.41 (m,4H), 1.64-1.75 (m,2H), 3.18 (t,2H) and 13.22 (s,lH). Examples 12-26 The compounds of Examples 12 to 26 were prepared by heating 2-bromo-5- (pentylthio)thiazolo[4,5- ]pyrimidin-7(4H)-one (product of Example 1 1) with 5 equivalents of the appropriate amine in tetrahydrofuran at 45°C for 5 hours. Example 12 2-[[3-(Dimethylamino)propyl]amino]-5-(pentylthio)thiazoIo[4,5-έ/]pyrimidin-7(4^T)- one MS: APCI (+ve) 356 (M+l) Example 13 MS: APCI (+ve) 370 (M+l) Example 14 2-[[2-(Dimethylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-rf]pyrimidin-7(4fl r )-one MS: APCI (+ve) 342 (M+l) Example 15 MS: APCI (+ve) 329 (M+l) Example 16 2-[[2-(AcetyIamino)ethyl]amino]-5-(pentylthio)thiazoIo[4,5^pyrimidin-7(4 -one MS: APCI (+ve) 356 (M+l) Example 17 (±)-2-[(2,3-Dihydoxypropyl)amino]-5-(pentylthio)thiazolo[4,5--i]pyrimidin-7(4H)-one MS: APCI (+ve) 345 (M+l) Example 18 2-[[2-(4-Morpholinyl)ethyl]amino]-5-(pentylthio)thiazolo[4,5-. |pyrimidin-7(4H)-one MS: APCI (+ve) 384 (M+l) Example 19 2-[(2-Methoxyethyl)amino]-5-(pentylthio)thiazolo[4,5-rf]pyrimidin-7(4£ -one MS: APCI (+ve) 329 (M+l) Example 20 2-[(l-MethyIethyl)amino]-5-(pentyIthio)thiazolo[4,5- ]pyrimidin-7(4JE -one MS: APCI (+ve) 313 (M+l) Example 21 2-(Cyclopropylamino)-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7(4JΪ)-one MS: APCI (+ve) 311 (M+l) Example 22 (±)-2-[(2-Hydoxypropyl)amino]-5-(pentylthio)thiazolo[4,5-£T|pyrimidin-7(4H)-one MS: APCI (+ve) 329 (M+l) Example 23 2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-(pentylthio)thiazoIo[4,5-rf]pyrimidin-7(4fl)- one MS: APCI (+ve) 359 (M+l) Example 24 2-[(2-Hydroxy-2-methyIpropyl)amino]-5-(pentylthio)thiazolo[4,5-£TIpyrimidin-7(4fl)- one MS: APCI (+ve) 343 (M+l) Example 25 2-[(2-HydroxyethyI)amino]-5-(pentylthio)thiazolo[4,5--f]pyrimidin-7(4H)-one MS: APCI (+ve) 315 (M+l) Example 26 (2S,3R)-3-Hydroxy-2-[(7-oxo-5-(pentyIthio)-4JΪ-thiazolo[4,5-f |pyrimidin-2-yl]- amino)butanamide MS: APCI (+ve) 372 (M+l) Examples 27-43 The compounds of Examples 27 to 43 were prepared by heating 7-chloro-5- (pentylthio)thiazolo[4,5-<f]pyrimidin-2-amine (product of Example 6, step a) with 5 equivalents of the appropriate amine in tetrahydrofuran at 45°C for 5 hours. Example 27 N 7 -[3-(Dimethylamino)propyl]-5-(pentylthio)thiazolo[4,5-rf]pyrimidine-2,7-diamine MS: APCI (+ve) 355 (M+l) Example 28 N 7 -[2-(Diethylaniino)ethyI]-5-(pentylthio)thiazolo[4,5-rf]pyrimidine-2,7-dianiine MS : APCI (+ve) 369 (M+ 1 ) Example 29 N 7 -[2-(DimethyIamino)ethyl]-5-(pentylthio)thiazolo[4,5-rf]pyrimidine-2,7-diamine MS: APCI (+ve) 341 (M+l) Example 30 3-[(2-Amino-5-(pentylthio)thiazolo[4,5-dTlpyrimidin-7-yI)amino]-l-propanol MS: APCI (+ve) 328 (M+l) Example 31 N 7 -CyclohexyI-5-(pentylthio)thiazolo[4,5-rf]pyrimidine-2,7-diamine MS: APCI (+ve) 352 (M+l) Example 32 (±)-3-[(2-Amino-5-((phenylmethyl)thio)thiazolo[4,5-d]pyrimidin-7-yI)amino]-l,2- propanediol MS : APCI (+ve) 344 (M+ 1 ) Example 33 MS: APCI (+ve) 328 (M+l) Example 34 5-(PentyIthio)-N 7 .propylthiazolo[4,5-rf]pyrimidine-2,7-diamine MS: APCI (+ve) 312 (M+l) Example 35 N 7 -Cyclopentyl-5-(pentylthio)thiazolo[4,5.J]pyrimidine-2,7-diamine MS: APCI (+ve) 338 (M+l) Example 36 /V 7 -CyclopropyI-5-(pentylthio)thiazolo[4,5-d]pyrimidine-2,7-diamine MS : APCI (+ve) 310 (M+ 1 ) Example 37 N 7 -(2-MethyIpropyI)-5-(pentylthio)thiazoIo[4,5-rf]pyrimidine-2,7-diamine MS: APCI (+ve) 326 (M+l) Example 38 (±)-l-[(2-Amino-5-(pentylthio)thiazolo[4,5-rf]pyrimidin-7-yI)amino]-2-propanol MS: APCI (+ve) 328 (M+l) Example 39 (exo)-/V 7 -Bicyclo[2.2.1]hept-2-yI-5-(pentylthio)thiazolo[4,5-rf]pyrimidine-2,7-diamine MS: APCI (+ve) 364 (M+l) Example 40 MS: APCI (+ve) 358 (M+l) Example 41 (±)-N 7 -(2-MethylbutyI)-5-(pentylthio)thiazoIo[4,5-rf]pyrimidine-2,7-diamine MS: APCI (+ve) 340 (M+l) Example 42 l-[[2-Amino-5-(pentylthio)thiazoIo[4,5-rf]pyrimidin-7-yl]amino]-2-methyl-2-propanol MS: APCI (+ve) 342 (M+l) Example 43 N 7 (2-AnunophenyI)methyl]-5-(pentylthio)thiazoIo[4,5-^pyrimidine-2,7-diamine MS: APCI (+ve) 375 (M+l) Examples 44-47 The compounds of Examples 44 to 47 were prepared from 2-amino-5,6-dihydro-5- thioxothiazolo[4,5-<f|pyrimidin-7(4H)-one, diisopropylethylamine and the appropriate alkyl halide in dimethyl sulphoxide/dimethylformamide at 60°C. A total of 5 equivalents of base and alkyl halide were added over 3 days. Example 44 2-Aπύno-5-[(2-phenoxyethyl)thio]thiazoIo[4,5-^pyriιnidin-7(4#)-one MS: APCI (+ve) 321 (M+l) Example 45 (£)-2-Amino-5-[(3-phenyl-2-propenyl) othio]thiazolo[4,5-rf]pyrimidin-7(4fl r )-one MS: APCI (+ve) 317 (M+l) Example 46 2-Amino-5-[[3-[2,4-bis(l,l-dimethylethyl)phenoxy]propyI]thio]thiazoIo[4,5-rf]- pyrimidin-7(4fl r )-one MS: APCI (+ve) 447 (M+l) Example 47 2-Amino-5-[[[(4-trifluoromethyI)phenyl]methyl]thio]thiazolo[4,5-J]pyrimidin-7(4/ϊ). one MS: APCI (+ve) 359 (M+l) Examples 48-65 The compounds of Examples 48 to 65 were prepared from 2-amino-5,6-dihydro-5- thioxothiazolo[4,5- ]pyrimidin-7(4H)-one (product of Example 3, step a), potassium t-butoxide and the appropriate benzyl halide in dimethyl sulphoxide at room temperature. A total of 1.2 equivalents of base and alkyl halide were used and a reaction time of 24 hours. Example 48 2-Amino-5-[[(3,5-dichlorophenyl)methyl]thio]thiazoIo[4,5-<f]pyrimidin-7(4iϊ) one MS: APCI (+ve) 359 (M+l) Example 49 MS: APCI (+ve) 359 (M+l) Example 50 2-Amino-5-[[(3,4-dichlorophenyl)methyl]thio]thiazoIo[4,5-rf]pyrimidin-7(4£0-one MS: APCI (+ve) 359 (M+l) Example 51 2-Amino-5-[[(3,5-dibromophenyl)methyI]thio]thiazolo[4,5- ]pyriιnidin-7(4J )-one MS: APCI (+ve) 449 (M+l) Example 52 2-Amino-5-[[(2-nJtrophenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7(4iϊ)-one MS: APCI (+ve) 336 (M+l) Example 53 2-Amino-5-[[(2-fluorophenyl)methyl]thio]thiazoIo[4,5- ]pyrimidin-7(4 -one MS: APCI (+ve) 309 (M+l) Example 54 2-Amino-5-[[(2-iodophenyl)methyl]thio]thiazoIo[4,5--flpyrimidin-7(4H r )-one MS: APCI (+ve) 417 (M+l) Example 55 2-Amino-5-[[(3-chlorophenyl)methyI]thio]thiazoIo[4,5-d]pyrimidin-7(4iζr)-one MS: APCI (+ve) 325 (M+l) Example 56 2-Amino-5-[[(2-chlorophenyl)methyI]thio]thiazolo[4,5-< ]pyrinιidin-7(4 J H r )-one MS: APCI (+ve) 325 (M+l) Example 57 2-Amino-5-[[(4-chloro-2-nitrophenyI)methyI]thio]thiazolo[4,5- jpyrimidin-7(4H)-one MS: APCI (+ve) 370 (M+l) Example 58 2-Amino-5-[[(3-chloro-4-methoxyphenyl)methyI]thio]thiazoIo[4,5-rf]pyrimidin-7(4 y)- one MS: APCI (+ve) 355 (M+l) Example 59 2-Amino-5-[[(2,3-dichIorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7(4 )-one MS: APCI (+ve) 359 (M+l) Example 60 2-Amino-5-[[(3,5-d luorophenyI)methyl]thio]thiazoIo[4,5--f]pyrimidin-7(4f )-one MS: APCI (+ve) 327 (M+l) Example 61 2-Amino-5-[[[(2,4-bis(trifluoromethyI)phenyI]methyl]thio]thiazoIo[4,5-d]pyrimidin- 7(4H)-one MS: APCI (+ve) 427 (M+l) Example 62 2-Amino-5-[[(2-bromophenyl)methyl]thio]thiazolo[4,5-< |pyrimidin-7(4 )- ne MS: APCI (+ve) 371 (M+l) Example 63 2-Amino-5-[[(2,3,4-trifluorophenyl)methyl]thio]thiazolo[4,5--flpyrimidin-7(4fr ) S: APCI (+ve) 345 (M+l) Example 64 2-Amino-5-[[(3-bromophenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7(4i?)-one MS: APCI (+ve) 369 (M+l) Example 65 2-Amino-5-[[(2-fluoro-3-methyIphenyl)methyI]thio]thiazolo[4,5-rf]pyrimidin-7(4H)- one MS: APCI (+ve) 323 (M+l) Examples 66-77 The compounds of Examples 66 to 77 were prepared from 7-chloro-5- [(phenylmethyl)thio]thiazolo[4,5- lpyrimidin-2-amine and the appropriate hydroxyamine in dimethyl sulphoxide at 45°C. A total of 6 equivalents of amine were added and the reaction time was 2 days. Example 66 3-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-7-yI]amino]-2,2- dimethyl-l-propanol MS: APCI (+ve) 376 (M+l) Example 67 (±)-α-[[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-7- yl] amino]methyl] benzenemethanol MS: APCI (+ve) 410 (M+l) Example 68 (R)-β-[[2-Amino-5-[(phenylmethyI)thio]thiazolo[4,5-J]pyrimidin-7- yI]amino]benzenepropanoI MS: APCI (+ve) 424 (M+l) Example 69 2-[[2-Amino-5-[(phenylmethyl)thio]thiazoIo[4,5-- ]pyrimidin-7-yI]amino]ethanol MS: APCI (+ve) 334 (M+l) Example 70 (2R)-2-[[2-Amino-5-[(phenylmethyI)thio]thiazoIo[4,5-d]pyrimidin-7-yl]amino]4- methylpentanol MS: APCI (+ve) 390 (M+l) Example 71 (±)-l-[[2-Amino-5-[(phenylmethyl)thio]thiazoIo[4,5-d]pyrimidin-7-yl]amino]-2- propanol MS: APCI (+ve) 348 (M+l) Example 72 (±)-β-[[2-Amino-5-[(phenylmethyl)thio]thiazoIo[4,5-rf]pyrimidin-7-yI]amino]-4- chlorobenzenepropanol MS: APCI (+ve) 458 (M+l) Example 73 (±)-3-[[2-Amino-5-[(phenylmethyl)thio]thiazoIo[4,5-rf]pyrimidin-7-yl]amino]-l,2- propanediol MS: APCI (+ve) 364 (M+l) Example 74 2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-7-yI]- propylamino]ethanoI MS: APCI (+ve) 376 (M+l) Example 75 (±)-l-[2-Amino-5-[(phen n-7-yl]-3-pyrrolidinol MS: APCI (+ve) 360 (M+l) Example 76 (±)-l-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-3-piperidinoI MS: APCI (+ve) 374 (M+l) Example 77 l-[2-Amino-5-[(phenylmethyI)thio]thiazoIo[4,5-rf]pyrimidin-7-yl]-4-piperidinoI MS: APCI (+ve) 374 (M+l) Examples 78-110 The compounds of Examples 78 to 110 were prepared from 7-chloro-5-[[3- phenoxyphenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-2-amine (prepared by the method of Example 1, step a) using the product of Example 5) and the appropriate hydroxyamine in tetrahydrofuran at 45°C. A total of 6 equivalents of amine were added and the reaction time was 2 days. Example 78 3-[[2-Amino-5-[[(3-phenoxyphenyI)methyl]thio]thiazolo[4,5-rf]pyrimidin-7-yl]amino]- 2,2-dimethyl-l -propanol MS : APCI (+ve) 468 (M+ 1 ) Example 79 (±)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7-yl] amino]-l-butanol MS: APCI (+ve) 454 (M+l) Example 80 (±)-α-[[[2-Amino-5-[[(3-phenoxyphenyI)methyI]thio]thiazolo[4,5-rf]pyrimidin-7-yI]- amino]methyI]benzenemethanol MS: APCI (+ve) 502 (M+l) Example 81 4-[[2-Amino-5-[[(3-phenoxyphenyI)methyl]thio]thiazolo[4,5-</]pyrimidin-7-yI]amino]- 1 -butanol MS : APCI (+ve) 454 (M+ 1 ) Example 82 6-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazoIo[4,5-d]pyrimidin-7-yl]amino]- 1-hexanol MS: APCI (+ve) 482 (M+l) Example 83 4-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7-yl]- amino]cycIohexanol MS: APCI (+ve) 480 (M+l) Example 84 (R)-β-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazoIo[4,5-rf]pyrimidin-7-yl]- aminojbenzenepropanol MS : APCI (+ve) 516 (M+ 1 ) Example 85 (±)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5 |pyrimidin-7-yl]- amino] - 1 -propanol MS: APCI (+ve) 440 (M+l) Example 86 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazoIo[4,5-- ]pyrimidin-7-yl]- aminojethanol MS: APCI (+ve) 426 (M+l) Example 87 (2R)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazoIo[4,5-d]pyrimidin-7-yI]- amino]-4-methylpentanol MS : APCI (+ve) 482 (M+ 1 ) Example 88 (±)-l-Amino-3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazoIo[4,5 |pyrimidin- 7-yl]amino]-2-propanoI MS: APCI (+ve) 455 (M+l) Example 89 (±)-l-[[2-Amino-5-[[(3-phenoxyphenyI)methyl]thio]thiazolo[4,5-ti]pyrimidin-7- yl]amino]-2-propanol MS: APCI (+ve) 440 (M+l) Example 90 2-[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7- yl]amino]methyI]-2-ethyl-l,3-propanediol MS: APCI (+ve) 498 (M+l) Example 91 (±)-β-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7- yI]amino]-4-chlorobenzenepropanol MS: APCI (+ve) 550 (M+l) Example 92 (±)-3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7- yl]amino]-l,2-propanediol MS: APCI (+ve) 456 (M+l) Example 93 2-[[2-[[2-Amino-5-[[(3-phenoxyphenyl)methyI]thio]thiazolo[4,5-rf]pyrimidin-7- yI]amino]ethyl]amino]ethanol MS: APCI (+ve) 469 (M+l) Example 94 3-[[2-Amino-5-[[(3-phenoxyphenyI)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yI]amino]- 1 -propanol MS: APCI (+ve) 440 (M+l) Example 95 (±)-α-[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7- yl]amino]methyl]-3,4-dichlorobenzenepropanol MS: APCI (+ve) 598 (M+l) Example 96 l-[[2-Amino-5-[[(3-phenoxyphenyl)methyI]thio]thiazolo[4,5-rf]pyrimidin-7-yl]amino]- 2-methyl-2-propanoI MS : APCI (+ve) 454 (M+ 1 ) Example 97 2-[2-[[2-Amino-5-[[(3-phenoxyphenyl)methyI]thio]thiazoIo[4,5-rf]pyrimidin-7- yI]amino]ethoxy]ethanoI MS: APCI (+ve) 470 (M+l) Example 98 5-[[2-Amino-5-[[(3-phenoxyphenyI)methyl]thio]thiazolo[4,5-α]pyrimidin-7-yl]amino]- 1 -pentanol MS: APCI (+ve) 468 (M+l) Example 99 (25)-2-[[2-Amino-5-[[(3-phenoxyphenyI)methyI]thio]thiazolo[4,5-rf]pyrimidin-7- yl]amino]-4-(methylthio)-l-butanol MS : APCI (+ve) 500 (M+ 1 ) Example 100 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7- yl]butylamino]ethanol MS: APCI (+ve) 482 (M+l) Example 101 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-J]pyrimidin-7- yl]propylamino]ethanol MS: APCI (+ve) 468 (M+l) Example 102 2,2'-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7- yI]imino]bisethanoI MS: APCI (+ve) 470 (M+l) Example 103 2-[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7-yl]-(2- hydroxyethyl)amino]methyl]phenoI MS: APCI (+ve) 532 (M+l) Example 104 3-[[2-Amino-5-[[(3-phenoxyphenyI)methyl]thio]thiazolo[4,5- |pyrimidin-7-yl]-(2- hydroxyethyI)amino]-l-propanol MS: APCI (+ve) 484 (M+l) Example 105 (±)-l-[2-Amino-5-[[(3-phenoxyphenyl)methyI]thio]thiazoIo[4,5-d]pyrimidin-7-yl]-3- pyrrolidinol MS : APCI (+ve) 452 (M+ 1 ) Example 106 ( ή rαn5)-l-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7-yl]- 4-hydroxy- -proIine p MS: APCI (+ve) 586 (M+l) Example 107 (±)-l-[2-Amino-5-[[(3-phenoxyphenyl)methyI]thio]thiazolo[4,5-rf]pyrimidin-7-yl]-3- piperidinemethanol MS: APCI (+ve) 480 (M+l) Example 108 (±)-l-[2-Amino-5-[[(3-phenoxyphenyI)methyl]thio]thiazolo[4,5-- Ipyrimidin-7-yl]-3- piperidinol MS : APCI (+ve) 466 (M+ 1 ) Example 109 (25)-l-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazoIo[4,5-rf]pyrimidin-7-yl]-2- pyrrolidinemethanol MS: APCI (+ve) 466 (M+l) Example 110 l-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-έflpyrimidin-7-yl]-4- piperidinol MS: APCI (+ve) 466 (M+l) Example 111 (2R)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyI]thio]thiazolo[4,5-. lpyriniidin-7- yl]amino]-l-butanol (a) 7-chloro-5-[[(3-phenoxyphenyl)methyl]thio]thiazoIo[4,5-έ ]pyrimidin-2-amine Prepared by the method of Example 1(a). m.p. 178-180°C MS: APCI (+ve) 401 (M+l) l H NMR: δ (DMSO) 4.37 (s,2H), 6.83-7.39 (m,9H) and 8.95 (s,2H). (b) (2R)-2-[[2-Amino-5-[[(3-phenoxyphenyI)methyl]thio]thiazoIo[4,5-rf]pyrimidin-7- yl]amino]-l -butanol Prepared by the method of Example 1(b). m.p. 108-111°C MS: APCI (+ve) 454 (M+l) l H NMR: δ (DMSO) 0.81 (t,3H), 1.41 (m,2H), 1.62 (m,2H), 3.36 (m,2H), 4.03 (m,lH), 4.31 (q,2H), 4.62 (s,lH), 6.78-7.38 (m,9H) and 8.00 (s,2H). Example 112 (25)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7- y 1] amino] - 1 -butanol Prepared by the method of Example 1(b). m.p. 111-114°C MS: APCI (+ve) 454 (M+l) H NMR: δ (DMSO) 0.81 (t,3H), 1.41 (m,2H), 1.62 (m,2H), 3.36 (m,2H), 4.02 (br d,lH), 4.32 (q,2H), 4.60 (s,lH), 6.79-7.40 (m,9H) and 8.04 (s,2H). Example 113 (2R)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7- yI]amino]-l-butanoI (a) 7-ChIoro-5-[[(3,4-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-2-amine Prepared by the method of Example 1(a) using the product of Example 3. m.p. 209-210°C MISS:: AAPPCCII((++vvee)) 345/6 (M+ 1 ) 1 H NMR: δ (DMSO) 4.45 (s,2H), 7.10-7.42 (m,3H) and 8.90 (br s,2H). (b) (2R)-2-[[2-Amino-5-[[(3,4-difluorophenyI)methyl]thio]thiazoIo[4,5--i]pyrimidin-7- yl]amino]-l-butanol Prepared by the method of Example 1(b) using the product of step a) above. MS: APCI(+ve) 398 (M+l) l H NMR: δ (DMSO) 0.82 (t,3H), 1.34-1.71 (m,4H), 3.37 (m,2H), 4.03 (br d,lH), 4.38 (q,2H), 4.62 (t,lH), 6.96 (d,lH), 7.06-7.40 (m,3H) and 8.02 (s,2H). Example 114 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazoIo[4,5-< Ipyrimidin-7-yl]anιino]- 1,3-propanediol Prepared by the method of Example 1(b). m.p. 220-222°C MS: APCI (+ve) 456 (M+l) l R NMR: δ (DMSO) 3.50 (t,4H), 4.13 (m,lH), 4.32 (s,2H), 4.60 (t,2H), 6.78-7.40 (m,10H) and 8.01 (s,2H). Example 115 2-[[2-Amino-5-[[(3-phenoxyphenyI)methyl]thio]thiazoIo[4,5-d]pyrimidin-7-yl]amino]- 2-methyl-l-propanoI Prepared by the method of Example 1(b) with 10 equivalents of amine, 45-65°C and reaction time of 3 weeks. Purification by chromatography on silica eluting with methanol/dichloromethane mixtures gave the title compound. m.p. 126-130°C MS: APCI (+ve) 454 (M+l) l H NMR: δ (DMSO) 1.30 (s,6H), 3.53 (d,2H), 4.33 (s,2H), 4.86 (t,lH), 6.28 (s,lH), 6.80-7.40 (m,9H) and 8.00 (s,2H). Example 116 2-[[2-Amino-5-[[(2,3-difluorophenyI)methyI]thio]thiazolo[4,5- |pyrimidin-7- yI]amino]-2-methyl-l-propanol Prepared by the method of Example 1(b) using the product of Example 113, step a), 10 equivalents of amine, 45-65°C and reaction time of 3 weeks. Purification by chromatography on silica eluting with methanol/dichloromethane mixtures gave the title compound. m.p. 231-234°C MS: APCI (+ve) 398 (M+l) l H NMR: δ (DMSO) 1.30 (s,6H), 3.53 (d,2H), 4.40 (s,2H), 4.84 (t,lH), 6.32 (s,lH), 7.10-7.40 (m,3H) and 8.03 (s,2H). Example 117 l-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-f ipyrimidin-7- yI]amino]-2-methyl-2-propanol The product from Example 1 13, step a) (O.lg) and l-amino-2-methyl-propan-2-ol (0.5g) in tetrahydrofuran (10ml) was heated in a sealed vessel at 100 °C for 18 hours. The mixture was evaporated to dryness and purified (HPLC, Novapak ® C18 column, 0.1% aqueous ammonium acetate:acetonitrile, gradient elution 70:30 to 0:100 over 15 minutes) to afford the title compound (0.05 lg). MS (APCI) 398 (M+H + , 100%). NMR δH (d 6 -DMSO) 8.05 (2H, s), 7.39-7.17 (2H, m), 7.16-7.05 (2H, m), 4.51 (1H, s), 5.23 (1H, d), 4.39 (2H, s), 3.37 (2H, d), 1.06 (6H, s). Example 118 5-[[(2,3-Difluorophenyl)methyl]thio]-N 7 -(2-fluoroethyI)thiazoIo[4,5-- ]pyrimidine-2,7- diamine The product from Example 113, step a) (O.lg), 2-fluoroethylamine hydrochloride (0.5g) and N,N-ethyldiisopropylarnine (0.4ml) in tetrahydrofuran: water (7ml, 5:2) was heated in a sealed vessel at 100 °C for 18 hours. The mixture was evaporated to dryness and purified (HPLC, Νovapak C18 column, 0.1% aqueous ammonium acetate:acetonitrile, gradient elution 70:30 to 0: 100 over 15 minutes) to afford the title compound (0.027g). MS (APCI) 372 (M+H + , 100%). ΝMR δH (d 6 -DMSO) 8.09 (2H, s), 7.36 (1H, t), 7.38-7.10 (3H, m), 4.57 (1H, t), 4.21 (3H,m), 3.71 (1H, q), 4.39 (2H, s), 3.63 (1H, q). Example 119 (lR-trans) 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyI]thio]thiazolo[4,5--/]pyrimidin- 7-yI]amino] -cyclopentanol The product from example 113 step a) (0.2g), (1R.2R) 2-aminocyclopentanol hydrochloride (l.Og) and N-ethyldiisopropylamine (1.2ml) in methanol (15ml) was heated in a sealed vessel at 120 °C for 90 mins. The mixture was evaporated to dryness and purified (HPLC, Νovapak ® C18 column, 0.1% aqueous ammonium acetate:acetonitrile, gradient elution 70:30 to 0: 100 over 15 minutes) to afford the title compound (0.098g). MS (APCI) 410 (M+H + , 100%). ΝMR δH (d 6 -DMSO) 8.04 (2H, s), 7.41-7.27 (2H, m), 7.20 (IH, d), 7.16-7.11 (IH, m), 4.76 (IH, d), 4.41 (2H, dd), 4.09 (IH, m), 3.95 (IH, m), 1.99 (IH, m), 1.89 (IH, m), 1.62 (2H, m), 1.49-1.36 (2H, m). Example 120 (25-frαns) 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin- 7-yl]amino]-cycIopentanol Prepared by the method of Example 119 using the product from Example 113, step a) and (iS,2S)-2-aminocyclopentanol hydrochloride. MS (APCI) 410 (M+H + , 100%). ΝMR δH (d 6 -DMSO) 8.03 (2H, s), 7.41-7.27 (2H, m), 7.20 (IH, d), 7.16-7.11 (IH, m), 4.76 (IH, d), 4.41 (2H, dd), 4.09 (IH, m), 3.96 (IH, m), 1.99 (IH, m), 1.89 (IH, m), 1.62 (2H, m), 1.49-1.36 (2H, m). Example 121 2-[[2-Amino-5-[(phenylmethyl)thio]thiazoIo[4,5-</]pyrimidin-7-yl]amino]-2-methyl-l- propanol Prepared by the method of Example 117 using the product of Example 1, step a) (0.6g) and 2-amino-2-methyl-propanol. Purification (Siθ 2 , ethyl acetate as eluant) gave the title compound (0.46g). MS (APCI) 362 (M+H + , 100%). NMR δH (d 6 -DMSO) 8.00 (2H, s), 7.42-7.20 (5H, m), 6.29 (IH, s), 4.86 (IH, s), 4.35 (2H, s), 3.56 (2H, d), 1.32 (6H, s). Example 122 2-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-7- yI]amino]- 1-propanol a) 2-[[2-Bromo-5-[(phenylmethyl)thio]thiazoIo[4,5-^pyrimidin-7-yl]amino]-2-methyl- 1 -propanol To a solution of the product from Example 121 (O.lg) in bromoform (5 ml) was added isoamylnitrite (0.13 ml) and the mixture heated at 60°C for 10 mins. The mixture was evaporated to dryness then purified (SiO 2 , ethyl acetate: dichloromethane 1:9 as eluant) to give the subtitle compound (0.043g). MS (APCI) 426 (M+H + , 100%). b) 2-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5--f|pyrimidin-7- y I] amino] -1 -propanol To a solution of the product from step a) (0.043g) in methanol (5ml) was added a saturated solution of methanolic methylamine (20ml) and the mixture strirred for 30 mins. The mixture was evaporated to dryness and purified (HPLC, Novapak ® C18 column, 0.1% aqueous ammonium acetate :acetonitrile, isocratic elution 70:30 over 15 minutes) to afford the title compound (0.026g). MS (APCI) 376 (M+H + , 100%). NMR δH (dg-DMSO) 8.49 (IH, d), 7.42-7.21 (5H, m), 6.34 (IH, s), 4.87 (IH, s), 4.35 (2H, s), 3.56 (2H, d), 2.94 (3H, d), 1.33 (6H, s). Example 123 2-[[2-[[5-[[(2,3-Difluoroρhenyl)methyl]thio]-2-[(phenyImethyI)amino]thiazolo[4,5- rf]pyrimidin-7-yI]amino]-2-methyI-l-propanol a) 2-[[2-Bromo-5-[[(2,3-difluorophenyl)methyl]thio]thiazoIo[4,5-d]pyrimidin-7- yl]amino]-2-methyl-l-propanol The sub-title compound was prepared by the method of Example 122, step a) using the product from Example 116. Purification (SiO 2 , ethyl acetate: dichloromethane 1 :9 as eluant) gave the subtitle compound (0.16g). MS (APCI) 461 (M+H + , 100%). b)2-[[2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(phenylmethyl)amino]thiazolo[4,5- d]pyrimidin-7-yl]amino]-2-methyl-l-propanol Prepared by the method of Example 122, step b) using the product from step a). Purification (SiO 2 , ethyl acetate: dichloromethane 1 :9 as eluant) gave the title compound (0.051g). MS (APCI) 488 (M+H + , 100%). NMR δH (d 6 -DMSO) 9.08(1H, d), 7.38-7.12 (8H, m), 6.42 (IH, s), 4.82 (IH, t), 4.59 (2H, s), 4.42 (2H, s), 3.54 (2H, d), 1.29 (6H, s). Example 124 5-[[(2,3-Difluorophenyl)methyl]thio]thiazoIo[4,5-d]pyrimidin-7(4H)-one To a solution of the product from Example 3 (l.Og) in tetrahydrofuran (50ml) was added isoamyl nitrite (3ml) and the mixture heated at 70°C for 2 hours. The mixture was evaporated to dryness and purified (SiO 2 , ethyl acetate: chloroform 1:9 as eluant) to give the title compound (0.6 lg). MS (APCI) 512 (M+JT, 100%). NMR δH (d 6 -DMSO) 13.19(1H, s), 9.61(1H, d), 7.44-7.33 (2H, m), 7.22-15 (IH, m), 4.59 (2H, s). Example 125-148 Example 125 to 148 were prepared by heating, the product of Example 113, step a) (5xl0 6 moles) with the appropriate amine (10 equivalents) and N-ethyldiisopropylamine (20 equivalents) in N-methylpyrrolidinone (0.3 ml) in a sealed vessel at 120°C for 16 hours. Example 125 (±)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7- yl]amino]-l-butanol MS (APCI) 398 (M+Kf, 100%). Example 126 (15,25)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyI]thio]thiazolo[4,5-ti]pyrimidin-7- yl]amino]-cyclohexanol MS (APCI) 424 (M+H + , 100%). Example 127 (±)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7- yl]amino]-l-propanoI MS (APCI) 384 (M+H + , 100%) Example 128 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyI]thio]thiazolo[4,5-rf]pyrimidin-7- yl]amino]-l -ethanol MS (APCI) 370 (M+H + , 100%). Example 129 (2R)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7- yl]amino]-4-methyI-l-pentanol MS (APCI) 426 (M+H + , 100%). Example 130 (±)-l-[[2-Amino-5-[[(2,3-difluorophenyl)methyI]thio]thiazolo[4,5-£Tlpyrimidin-7- yl]amino]-2-propanoI MS (APCI) 384 (M+H + , 100%). Example 131 2-[[2-Amino-5-[[(2,3-difluorophenyI)methyI]thio]thiazolo[4,5-d]pyrimidin-7- yl]amino]-2-methyl-l,3-propanedioI MS (APCI) 414 (M+H + , 100%). Example 132 l-[[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazoIo[4,5-rf]pyrimidin-7- yl]amino]methyl]-cyclohexanol MS (APCI) 438 (M+H + , 100%). Example 133 (2R)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-.i]pyrimidin-7- yl]amino]-l-butanol MS (APCI) 398 (M+H + , 100%). Example 134 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-J]pyrimidin-7-yI]-(2- aminoethyl)amino]-l-ethanol MS (APCI) 413 (M+H + , 100%). Example 135 2-[2-[[2-Amino-5-[[(2,3-difluorophenyI)methyl]thio]thiazoIo[4,5-£f]pyrimidin-7- yl]amino]ethoxy]-l-ethanol MS (APCI) 414 (M+H + , 100%). Example 136 (α5)-α-[(lR)-l-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5- έ/]pyrimidin-7-yl]methylamino]ethyl]-benzenemethanol MS (APCI) 474 (M+H + , 100%). Example 137 l-[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-t/]pyrimidin-7-yl]-4- piperidinol MS (APCI) 410 (M+H + , 100%). Example 138 5-[[(2,3-Difluorophenyl)methyl]thio]-N r -ethyl-thiazolo[4,5--/]pyrimidine-2,7-diamine MS (APCI) 354 (M+H + , 100%). Example 139 5-[[(2,3-Difluorophenyl)methyl]thio]-N 7 -(2-propenyl)-thiazolo[4,5-rf]pyrimidine-2,7- diamine MS (APCI) 366 (M+H\ 100%). Example 140 2-Bromo-5-[(phenylmethyl)thio]thiazolo[4,5-J]pyrimidin-7(4H)-one To a solution of the product from Example 9 (2g) in bromoform (100ml) was added isoamyl nitrite (2ml) and the mixture heated at 80°C for 2 hour. The mixture was evaporated to dryness and purified (SiO 2 , dichloromethane as eluant) to give the title compound (0.76g). MS (APCI) 355, 354 (M+H + ), 354 (100%). Example 141 (15,25)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazoIo[4,5-rf]pyrimidin-7- yl]amino]-l-phenyl-l,3-propanediol MS (APCI) 476 (M+H + , 100%). Example 142 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5--/]pyrimidin-7- yl]amino]-l,3-propanediol MS (APCI) 400 (M+IT, 100%). Example 143 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7- yl]amino]-l-ethanol MS (APCI) 370 (M+H + , 100%). Example 144 (±)-5-[[(2,3-Difluorophenyl)methyl]thio]-N 7 -(2-methoxy-l-methylethyl)-thiazolo[4,5- rf]pyrimidine-2,7-diamine MS (APCI) 398 (M+H + , 100%). Example 145 N 7 -CyclopropyI-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-<flpyrimidine-2,7- diamine MS (APCI) 366 (M+H + , 100%). Example 146 (±)-2-[[2-Amino-5-[[(2,3-difluorophenyI)methyl]thio]-thiazoIo[4,5-tf]pyrimidin-7- yl]amino]-l-propanol MS (APCI) 384 (M+H + , 100%). Example 147 4-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-./]pyrimidin-7- yl]amino]-l-butanol MS (APCI) 398 (M+H + , 100%). Example 148 5-[[(2,3-Difluorophenyl)methyl]thio]-N 7 -[2-( -imidazol-4-yl)ethyI]-thiazolo[4,5- d]pyrimidine-2,7-diamine MS (APCI) 420 (M+H + , 100%). Example 149-165 The compounds of Example 149 to 165 were prepared by heating 2-[[2-bromo-5-[[(2,3- difluorophenyl)methyl]thio]thiazolo[4,5-(i]pyrimidin-7-yl]amino]-2-methyl-l-propanol (prepared according to the method of Example 122, step a) using the product of Example 116) (5xl0 6 moles) with the appropriate amine (2 equivalents ) and N-ethyldiisopropylamine (2 equivalents) in tetrahydrofuran (0.5 ml) at 50-60°C for 16 hours. Example 149 N-[5-[[(2,3-Difluorophenyl)methyI]thio]-7-[(2-hydroxy-l,l- dimethylethyl)amino]thiazolo[4,5-- lpyrimidin-2-yl]-serine, methyl ester MS (APCI) 500 (M+H + , 100%). Example 150 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(l-methylethyl)amino]thiazolo[4,5- rf]pyrimidin-7-yl]amino]-2-methyl-l-propanol MS (APCI) 440 (M+H + , 100%). Example 151 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-(ethylamino)thiazoIo[4,5-rf]pyrimidin-7- yl]amino]-2-methyl-l-propanol MS (APCI) 426 (M+IT, 100%). Example 152 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(l^r-indol-3- yI)ethyl]amino]thiazolo[4,5-rf]pyrimidin-7-yI]amino]-2-methyl-l-propanol MS (APCI) 541 (M+∑T, 100%). Example 153 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(l- naphthalenylmethyl)amino]thiazolo[4,5-- |pyrimidin-7-yl]amino]-2-methyl-l- propanol MS (APCI) 538 (M+H + , 100%). Example 154 2-[[5-[[(2,3-DifluorophenyI)methyI]thio]-2-[(l,2-diphenyIethyl)amino]thiazolo[4,5- rf]pyrimidin-7-yI]amino]-2-methyl-l-propanoI MS (APCI) 578 (M+H + , 100%). Example 155 2-[[5-[[(2,3-DifluorophenyI)methyl]thio]-2-[(2,2,2-trifluoroethyI)amino]thiazolo[4,5- -/]pyrimidin-7-yl]amino]-2-methyl-l-propanoI MS (APCI) 480 (M+H + , 100%). Example 156 2-[[5-[[(2,3-DifluorophenyI)methyI]thio]-2-[[(3,4,5- trimethoxyphenyl)methyl]aπιino]thiazolo[4,5-d]pyrimidin-7-yI]anιino]-2-methyl-l- propanol MS (APCI) 578 (M+H + , 100%). Example 157 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(l,l-dimethylethyI)amino]thiazoIo[4,5- -/]pyrimidin-7-yI]amino]-2-methyl-l-propanol MS (APCI) 454 (M+H + , 100%). Example 158 2-[[5-[[(2,3-DifluorophenyI)methyI]thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5- rf]pyrimidin-7-yl]amino]-2-methyl-l-propanol MS (APCI) 508 (M+H + , 100%). Example 159 2-[[5-[[(2,3-Difluorophenyl)methyI]thio]-2-[(4-methylcyclohexyI)amino]thiazolo[4,5- £Tjpyrimidin-7-yl]amino]-2-methyI-l-propanol MS (APCI) 494 (M+H + , 100%). Example 160 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-l,l- dimethyIethyl)aniino]thiazolo[4,5-<fIpyrimidin-2-yI]amino]-acetamide MS (APCI) 455 (M+H + , 100%). Example 161 2-[[2-[[2-(4-Aminophenyl)ethyl]amino]-5-[[(2,3- difluorophenyl)methyl]thio]thiazolo[4,5--f|pyrimidin-7-yl]amino]-2-methyI-l- propanol MS (APCI) 517 (M+H + , 100%). Example 162 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5- rf]pyrimidin-7-yl]amino] -2-meth l- 1 -propanol MS (APCI) 444 (M+H + , 100%). Example 163 2-[[2-(CyclopropyIamino)-5-[[(2,3-difluorophenyl)methyI]thio]thiazolo[4,5- rf]pyrimidin-7-yl]amino]-2-methyl-l-propanoI MS (APCI) 438 (M+H + , 100%). Example 164 (±)-2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-l,l- dimethyIethyl)amino]thiazoIo[4,5-rf]pyrimidin-2-yl]amino]-l-pentanol MS (APCI) 484 (M+H + , 100%). Example 165 2-[[5-[[(2,3-Difluorophenyl)methyI]thio]-2-[[2-(2- hydroxyethoxy)ethyl]anuno]thiazoIo[4,5-rf]pyrimidin-7-yl]amino]-2-methyl-l- propanol MS (APCI) 486 (M+H÷, 100%). Example 166 2-Bromo-5-[[(2,3-difluorophenyl)methyl]thio]-thiazoIo[4,5--i]pyrimidin-7(4fl r )-one To a solution of the product from Example 3 (0.2g) in bromoform (5ml) was added isoamyl nitrite (0.25ml) and the mixture heated at 70°C for 1 hour. The mixture was evaporated to dryness and purified (SiO 2 , dichloromethane as eluant) to give the title compound (0.08g). NMR δH (de-DMSO) 7.42-7.14 (3H, m), 4.55 (2H, s). Example 167-173 The compounds of Example 167 to 173 were prepared by heating, the product of Example 166 with the appropriate amine (1.2 equivalents) and N-ethyldiisopropylamine (0.1ml) in tetrahydrofuran (0.2 ml) at 40°C for 16 hours. Example 167 N-[5-[[(2,3-Difluorophenyl)methyl]thio]-6,7-dihydro-7-oxo-thiazolo[4,5-- lpyrimidin- 2-yl]-DL-serine, methyl ester MS (APCI) 429 (M+H + , 100%). Example 168 5-[[(2,3-DifluorophenyI)methyI]thio]-2-[(l-methylethyl)amino]-thiazolo[4,5- /]pyrimidin-7(4H)-one MS (APCI) 369 (M+H + , 100%). Example 169 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(lfl r -indol-3-yl)ethyI]amino]-thiazoIo[4,5- - Jpyrimidin-7(4//)-one. MS (APCI) 470 (M+H + , 100%). Example 170 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-6,7-dihydro-7-oxo-thiazolo[4,5-rf]pyrimidin- 2-yl]amino] -acetamide MS (APCI) 384 (M+H + , 100%). Example 171 2-[[2-(4-Aminophenyl)ethyl]amino]-5-[[(2,3-difluorophenyI)methyl]thio]-thiazoIo[4,5- . jpyrimidin-7(4/f)-one MS (APCI) 446 (M+H + , 100%). Example 172 5-[[(2,3-DifluorophenyI)methyl]thio]-2-[(2-fluoroethyl)amino]-thiazolo[4,5- -/]pyrimidin-7(4Zf)-one MS (APCI) 373 (M+H + , 100%). Example 173 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-hydroxyethoxy)ethyI]amino]- thiazolo[4,5-rf]pyrimidin-7(4ZF)-one MS (APCI) 415 (M+H + , 100%). Example 174-218 Example 174 to 218 were prepared by heating the product of Example 122, step a) (5xl0 6 moles) with the appropriate amine (2 equivalents) and N-ethyldiisopropylamine (2 equivalents) in N-methylpyrrolidinone (0.1 ml) in a sealed vessel at 60°C for 5 hours. Example 174 2-[[2-(Cyclohexylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yI]amino]- 2-methyI-l-propanol MS (APCI) 444 (M+H", 100%). Example 175 2-[[2-[(l,l-Dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5--f|pyrimidin-7- yl]amino]-2-methyl-l-propanol MS (APCI) 418 (M+H + , 100%). Example 176 N-[7-[(2-Hydroxy-l,l-dimethylethyI)amino]-5-[(phenylmethyI)thio]thiazoIo[4,5- rf]pyrimidin-2-yI]-DL-alanine, methyl ester MS (APCI) 448 (M+H * . 100%). Example 177 4-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- rf]pyrimidin-2-yl]amino]-cyclohexanol MS (APCI) 460 (M+JT, 100%). Example 178 2-Methyl-2-[[2-[(4-phenylbutyl)amino]-5-[(phenylmethyl)thio]thiazoIo[4,5- rf]pyrimidin-7-yl]amino]-l-propanol MS (APCI) 494 (M+H + , 100%). Example 179 2-Methyl-2-[[5-[(phenylmethyI)thio]-2-[[(tetrahydro-2- furanyI)methyl]amino]thiazoIo[4,5-rf]pyrimidin-7-yl]amino]-l-propanoI MS (APCI) 446 (M+H + , 100%). Example 180 2-MethyI-2-[[2-[(l-methylethyl)amino]-5-[(phenyImethyl)thio]thiazolo[4,5- rf]pyrimidin-7-yI]amino]-l-propanol MS (APCI) 404 (M+H + , 100%). Example 181 2-[[2-[[2-(4-AminophenyI)ethyl]amino]-5-[(phenylmethyI)thio]thiazolo[4,5- rf]pyrimidin-7-yI]amino]-2-methyl-l-propanol MS (APCI) 481 (M+H + , 100%). Example 182 N-[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyI)thio]thiazolo[4,5- d]pyrimidin-2-yl]-L-valine, ethyl ester MS (APCI) 490 (M+ET, 100%). Example 183 (25)-2-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- -f]pyrimidin-2-yl]amino]-4-methyl-pentanamide. MS (APCI) 475 (M+H + , 100%). Example 184 2-MethyI-2-[[2-[(2-phenylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- rf]pyrimidin-7-yI]amino]-l-propanol MS (APCI) 466 (M+H + , 100%). Example 185 2-[[2-[[(4-Aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- rf]pyrimidin-7-yl]amino]-2-methyl-l-propanoI MS (APCI) 467 (M+H + , 100%). Example 186 2-Methyl-2-[[5-[(phenyImethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5- rf]pyrimidin-7-yl]amino]-l-propanol MS (APCI) 472 (M+H + , 100%). Example 187 2-[[2-[(2-FIuoroethyl)amino]-5-[(phenyImethyI)thio]thiazoIo[4,5- /]pyrimidin-7- yl]amino]-2-methyl-l-propanol MS (APCI) 408 (M+H + , 100%). Example 188 2-Methyl-2-[[2-[[(3-nitrophenyI)methyϊ]amino]-5-[(phenylmethyl)thio]thiazoIo[4,5- rf]pyrimidin-7-yI]amino]-l -propanol MS (APCI) 497 (M+H + , 100%). Example 189 (αΛ)-α-[(15)-l-[[7-[(2-Hydroxy-l,l-dimethyIethyI)amino]-5- [(phenylmethyl)thio]thiazoIo[4,5-rf]pyrimidin-2-yl]amino]ethyl]-benzenemethanoI MS (APCI) 496 (M+H + , 100%). Example 190 2-Methyl-2-[[5-[(phenylmethyI)thio]-2-[[(3,4,5- trimethoxyphenyl)methyl]amino]thiazolo[4,5-f |pyrimidin-7-yI]amino]-l-propanoI MS (APCI) 542 (M+H + , 100%). Example 191 2-MethyI-2-[[2-[(lR-trans)-(2-phenylcyclopropyl)amino]-5- [(phenylmethyl)thio]thiazoIo[4,5-rf]pyrimidin-7-yl]amino]-l-propanoI MS (APCI) 478 (M+H + , 100%). Example 192 2-[[2-[[2-(liy-Indol-3-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-- |pyrimidin- 7-yl]amino]-2-methyl-l-propanol MS (APCI) 505 (M+HT, 100%). Example 193 2-[[2-[(l,l-Dimethylpropyl)amino]-5-[(phenylmethyl)thio]thiazoIo[4,5-rf]pyrimidin-7- yI]amino]-2-methyl-l-propanoI MS (APCI) 432 (M+H + , 100%). Example 194 (±)-2-Methyl-2-[[2-[(l-methylbutyI)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- rf]pyrimidin-7-yI]amino]-l-propanol MS (APCI) 432 (M+H + , 100%). Example 195 (±)-2-MethyI-2-[[2-[(l-methylhexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- d] pyrimidin-7-yl] amino]-l -propanol MS (APCI) 460 (M+H + , 100%). Example 196 2-[[2-[[(2-AminophenyI)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- rf]pyrimidin-7-yl]amino]-2-methyI-l-propanol MS (APCI) 467 (M+H + , 100%). Example 197 2-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenyImethyl)thio]thiazolo[4,5- d]pyrimidin-2-yI]amino] -1 ,3-propanediol MS (APCI) 436 (M+H + , 100%). Example 198 2-[[2-[[2-(EthyIthio)ethyl]amino]-5-[(phenylmethyI)thio]thiazolo[4,5-rf]pyrimidin-7- yl]amino]-2-methyl-l-propanoI MS (APCI) 450 (M+H + , 100%). Example 199 (25)-2-[[7-[(2-Hydroxy-l,l-dimethyIethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- rf]pyrimidin-2-yl]amino]-3,3-dimethyI-l-butanol MS (APCI) 462 (M+H + , 100%). Example 200 (tx5)-α-[(lR)-l-[[7-[(2-Hydroxy-l,l-dimethyIethyl)amino]-5- [(phenylmethyl)thio]thiazolo[4,5-.i]pyrimidin-2-yl]amino]-2-methoxyethyI]- benzenemethanol MS (APCI) 526 (M+H + , 100%). Example 201 2-[[2-(EthyIamino)-5-[(phenylmethyI)thio]thiazolo[4,5-< |pyrimidin-7-yI]amino]-2- methyl-l-propanol MS (APCI) 390 (M+H + , 100%). Example 202 2-[[2-[[[3-FIuoro-5-(trifluoromethyl)phenyl]methyI]amino]-5- [(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-7-yI]amino]-2-methyl-l-propanol MS (APCI) 538 (M+H + , 100%). Example 203 (±)-2-Methyl-2-[[2-[(l-methyIpropyI)amino]-5-[(phenylmethyI)thio]thiazolo[4,5- rf]pyrimidin-7-yl]amino]-l-propanoI MS (APCI) 418 (M+lT, 100%). Example 204 2-[[2-[[(4-Methoxyphenyl)methyl]amino]-5-[(phenyImethyl)thio]thiazolo[4,5- d]pyrimidin-7-yl]amino]-2-methyI-l-propanoI MS (APCI) 482 (M+H + , 100%). Example 205 2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyI)thio]thiazolo[4,5--i]pyrimidin-7- yl]amino]-2-methyl-l-propanol MS (APCI) 406 (M+H + , 100%). Example 206 2-[[2-[[2-(l -Imidazol-4-yl)ethyI]amino]-5-[(phenylmethyI)thio]thiazolo[4,5- J]pyrimidin-7-yI]amino]-2-methyI-l-propanol MS (APCI) 456 (M+H + , 100%). Example 207 2-[[2-[(DiphenyImethyl)amino]-5-[(phenyImethyl)thio]thiazoIo[4,5-- |pyrimidin-7- yI]amino]-2-methyl-l-propanol MS (APCI) 528 (M+H + , 100%). Example 208 (25)-2-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazoIo[4,5- d]pyrimidin-2-yl]amino]-l-butanol MS (APCI) 434 (M+H*. 100%). Example 209 2-[[2-[(2,2-Diethoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-<f]pyrimidin-7- yl]amino]-2-methyl-l-propanol MS (APCI) 478 (M+H + , 100%). Example 210 4-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- J]pyrimidin-2-yl]amino]-l-butanoI MS (APCI) 434 (M+H + , 100%). Example 211 (15,25)-2-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5- [(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-2-yl]amino]-cyclohexanol. MS (APCI) 460 (M+H + , 100%). Example 212 (±)-2-[[2-[(2-Hydroxy-l-methylethyl)amino]-5-[(phenyImethyl)thio]thiazoIo[4,5- d]pyrimidin-7-yl]amino]-2-methyl-l-propanol MS (APCI) 420 (M+H + , 100%). Example 213 2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- rf]pyrimidin-7-yl]amino]-2-methyl-l-propanol MS (APCI) 450 (M+H + , 100%). Example 214 (±)-2-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- rf]pyrimidin-2-yI]amino]-l-pentanol MS (APCI) 448 (M+H + , 100%). Example 215 2-[[7-[(2-Hydroxy-l,l-dimethyIethyl)amino]-5-[(phenylmethyI)thio]thiazoIo[4,5- rf]pyrimidin-2-yl]amino]-acetamide MS (APCI) 419 (M+H + , 100%). Example 216 (±)-2-[[2-[[l-(4-Fluorophenyl)ethyl]amino]-5-[(phenyImethyl)thio]thiazolo[4,5- rf]pyrimidin-7-yl]amino]-2-methyl-propanoI MS (APCI) 484 (M+H + , 100%). Example 217 (lR,2S)-2-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5- [(phenyImethyl)thio]thiazolo[4,5-rf]pyrimidin-2-yl]amino]-cyclohexanol MS (APCI) 460 (M+H + , 100%). Example 218 (α5)-α-[(lR)-l-[[7-[(2-Hydroxy-l,l-dimethyIethyl)amino]-5- [(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-2-yl]amino]ethyl]-benzenemethanol MS (APCI) 496 (M+H + , 100%). Example 219 2-Bromo-7-chIoro-5-[(phenylmethyl)thio]-thiazoIo[4,5-rf]pyrimidine To a solution of the product from Example 1, step a) (lOg) in bromoform (300ml) was added t-butylnitrite (10ml) and the mixture heated at 60°C for 30 mins. The mixture. was evaporated to dryness then purified (SiO 2 , isohexane: dichloromethane 1 : 1 as eluant) to give the title compound (7.5g). MS (APCI) 373 (M+H + , 100%). NMR δH (d 6 -DMSO) 7.47-7.24 (5H, m), 4.49 (2H, s). Example 220 7-Chloro-N-methyl-5-[(phenylmethyl)thio]-thiazolo[4,5--/]pyrimidin-2-amine A solution of the product from Example 219 (0.3g) in tetrahydrofuran (2ml) containing methylamine (2.0 molar in THF:0.81ml) was stirred for 16 hours. The mixture was evaporated to dryness then purified (SiO 2 , ethyl acetate:dichloromethane 1:9 as eluant) to give the title compound (295mg). MS (APCI) 323 (M+H + , 100%). NMR δH (d 6 -DMSO) 9.30 (IH, s), 7.46-7.22 (5H, m), 4.40 (2H, s), 3.05 (3H, s). Example 221-223 Examples 221 to 223 were prepared by heating the product of Example 220 (2.5x10 "6 moles) with the appropriate amine (2 equivalents) and N-ethyldiisopropylamine (3 equivalents) in N-methylpyrrolidinone (0.1ml) in a sealed vessel at 100°C for 10 hours. Example 221 (±)-2-[[2-(Methylamino)-5-[(phenylmethyI)thio]thiazolo[4,5-£Tipyrimidin-7-yl]amino]- 1 -propanol MS (APCI) 362 (M+H + , 100%). Example 222 (2R)-4-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-7- y 1] amino] - 1 -pentanol MS (APCI) 404 (M+H + , 100%). Example 223 N-[2-(MethyIamino)-5-[(phenylmethyl)thio]thiazoIo[4,5-rf]pyrimidin-7-yl]-L-serine, ethyl ester MS (APCI) 420 (M+H + , 100%). Example 224 7-Chloro-5-[(phenyImethyl)thio]-N-[(tetrahydro-2-furanyl)methyl]-thiazolo[4,5- rf]pyrimidin-2-amine Prepared according to the method of Example 220 using the product of Example 219 and tetrahydrofurfurylamine . MS (APCI) 393 (M+H + , 100%). NMR δH (d 6 -DMSO) 9.50 (IH, s), 7.47-7.19 (5H, m), 4.39 (2H, s), 4.06 (IH, m) 3.82 (IH, m), 3.66 (2H, m), 3.50 (IH, m), 2.00-1.53 (4H, m). Examples 225-228 Examples 225-228 were prepared by the method of Example 221, using the product of Example 224. Examples 225 (±)-2-[[5-[(PhenyImethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5- rf]pyrimidin-7-yl]amino]-l-butanol MS (APCI) 446 (M+H + , 100%). Examples 226 (±)-2-[[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5- d]py rimidin-7-yI]amino] - 1 -propanol MS (APCI) 432 (M+H + , 100%). Examples 227 (2R)-4-Methyl-2-[[5-[(phenyImethyl)thio]-2-[[(tetrahydro-2- furanyl)methyI]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-l-pentanol MS (APCI) 474 (M+H + , 100%). Examples 228 N-[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5- rf]pyrimidin-7-yl]-L-serine, ethyl ester MS (APCI) 490 (M+H + , 100%). Example 229 2-[2-[[7-Chloro-5-[(phenyImethyI)thio]thiazolo[4,5-- ]pyrimidin-2-yl]amino]ethoxy]-l- ethanol Prepared according to the method of Example 220 using the product of Example 219 (0.3g) and 2-(2-aminoethoxy)ethanol. MS (APCI) 397 (M+H + , 100%). Example 230 (±)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyI)thio]thiazoIo[4,5- rf]pyrimidin-7-yl]amino]-l-propanol Prepared by the method of Example 221, using the product of Example 229. MS (APCI) 436 (M+H + , 100%). Example 231 4-[2-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]- benzenesulfonamide A solution of the product from Example 219 (0.3g) in tetrahydrofuran (2ml) containing 4- (2-aminoethyl)benzenesulfonamide (0.161 g) and N-ethyldiisopropylamine (0.5 ml) was stirred for 16 hours. The mixture was evaporated to dryness then purified (SiO 2 , ethyl acetate:dichloromethane 4:6 as eluant) to give the title compound (310mg). MS (APCI) 492 (M+H + , 100%). ΝMR δH (d 6 -DMSO) 9.45 (IH, s), 7.78-7.23 (9H, m), 4.41 (2H, s), 3.77 (2H, s) 3.02 (2H, t). Examples 232-235 Examples 232-235 were prepared by the method of Example 221, using the product of Example 231. Example 232 (±)-4-[2-[[7-[[l-(Hydroxymethyl)propyl]amino]-5-[(phenyImethyl)thio]thiazolo[4,5- rf]pyrimidin-2-yI]amino]ethyl]-benzenesuIfonamide MS (APCI) 545 (M+H + , 100%). Example 233 (±)-4-[2-[[7-[(2-Hydroxy-l-methylethyI)amino]-5-[(phenylmethyI)thio]thiazoIo[4,5- rf]pyrimidin-2-yl]amino]ethyl]-benzenesul onamide MS (APCI) 531 (M+H + , 100%). Example 234 4-[2-[[7-[[(lR)-l-(Hydroxymethyl)-3-methylbutyI]amino]-5- [(phenylmethyl)thio]thiazoIo[4,5-rf]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide. MS (APCI) 573 (M+ET, 100%). Example 235 (±)-4-[2-[[7-[(2-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide MS (APCI) 531 (M+H + , 100%). Example 236 7-Chloro-N-[2-(lJΪ-imidazol-4-yI)ethyl]-5-[(phenylmethyl)thio]- thiazolo[4,5- d]pyrimidin-2-amine Prepared according to the method of Example 231 using the product of Example 219 and histamine. MS (APCI) 403 (M+H + , 100%). NMR δH (d 6 -DMSO) 11.86 (IH, s), 9.42 (IH, s), 7.56 (IH, s), 7.56-7.23 (5H, m), 6.87 (IH, s), 4.41 (2H, s) 3.73 (2H, m), 2.85 (2H,t). Examples 237-248 Examples 237-248 were prepared by the method of Example 221, using the product of Example 236. Example 237 N 7 -EthyI-/V 2 -[2-(liy-imidazol-4-yl)ethyI]-5-[(phenylmethyI)thiothiazolo[4,5- rf]pyrimidine-2,7-diamine MS (APCI) 412 (M+H + , 100%). Example 238 N 2 -[2-(liϊ-Imidazol-4-yl)ethyl]-5-[(phenylmethyI)thio]-N 7 -(3-pyridinylmethyl)- thiazolo[4,5-^pyrimidine-2,7-diamine MS (APCI) 475 (M+H + , 100%). Example 239 (±)-2-[[2-[[2-(l J H r -ImidazoI-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazoIo[4,5- rf]pyrimidin-7-yI]amino]- 1 -butanol MS (APCI) 456 (M+H + , 100%). Example 240 (±)-2-[[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyI)thio]thiazolo[4,5- rf]pyrimidin-7-yl]amino]- 1-propanol MS (APCI) 442 (M+H + , 100%). Example 241 (2R)-2-[[2-[[2-(lfl r -Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyI)thio]thiazolo[4,5- rf]pyrimidin-7-yl]amino]-4-methyl-l-pentanol MS (APCI) 484 (M+lT, 100%). Example 242 (±)-l-[[2-[[2-(l y-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyI)thio]thiazoIo[4,5- rf]pyrimidin-7-yl]amino]-2-propanol MS (APCI) 442 (M+H + , 100%). Example 243 5-[[2-[[2-(l - ' -Imidazol-4-yl)ethyI]amino]-5-[(phenyImethyl)thio]thiazoIo[4,5- -/]pyrimidin-7-yl]amino]-l -pentanol MS (APCI) 470 (M+H + , 100%). Example 244 l-[2-[[2-(lH-Imidazol-4-yI)ethyl]amino]-5-[(phenylmethyl)thio]thiazoIo[4,5- rf]pyrimidiπ-7-yl]-4-(phenylmethyl)-4-piperidinol MS (APCI) 558 (M+H + , 100%). Example 245 (±)-l-[2-[[2-(l -Imidazol-4-yl)ethyI]amino]-5-[(phenyImethyI)thio]thiazoIo[4,5- rf]pyrimidin-7-yl]-3-piperidinecarboxamide MS (APCI) 495 (M+H + , 100%). Example 246 2-[Ethyl[2-[[2-(lfr-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- rf]pyrimidin-7-yl]amino]-l-ethanoI MS (APCI) 456 (M+H + , 100%). Example 247 N -[2-(lfT-Imidazol-4-yI)ethyl]-N 7 ^V 7 -dimethyl-5-[(phenylmethyl)thio]- thiazoIo[4,5- rf]pyrimidine-2,7-diamine MS (APCI) 412 (M+H + , 100%). Example 248 N 7 -[2-(Diethylamino)ethyI]-N -ethyl-/V 2 -[2-(liϊ-imidazol-4-yl)ethyl]-5- [(phenylmethyl)thio]-thiazoIo[4,5-έ/]pyrimidine-2,7-diamine MS (APCI) 511 (M+H + , 100%). Example 249 7-Chloro-N-(2-phenoxyethyl)-5-[(phenylmethyl)thio]-thiazolo[4,5-d]pyrimidin-2- amine Prepared by the method of Example 231 , using the product of Example 219 and 2-phenoxyethylamine. MS (APCI) 429 (M+H + , 100%). NMR δH (d 6 -DMSO) 9.65 (IH, s), 7.46-6.93 (10H, m), 4.41 (2H, s), 4.20 (2H, t), 3.87 (2H, m). Examples 250-255 Examples 250-255 were prepared by the method of Example 221, using the product of Example 249. Example 250 /V 2 -(2-Phenoxyethyl)-5-[(phenylmethyI)thio]-/V 7 -(3-pyridinylmethyl)-thiazolo[4,5- rf]pyrimidine-2,7-diamine MS (APCI) 501 (M+HT, 100%). Example 251 N 2 -(2-Phenoxyethyl)-N 7 -[l-(phenylmethyI)-4-piperidinyI]-5-[(phenylmethyl)thio]- thiazolo[4,5-d]pyrimidine-2,7-diamine MS (APCI) 583 (M+H + , 100%). Example 252 2-Methyl-2-[[2-[(2-phenoxyethyI)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- < Jpyrimidin-7-yl]amino]-l -propanol. MS (APCI) 482 (M+H + , 100%). Example 253 (±)-2-[[2-[(2-PhenoxyethyI)amino]-5-[(phenylmethyl)thio]thiazoIo[4,5-rf]pyrimidin-7- yl]amino] - 1 -propanol MS (APCI) 468 (M+H + , 100%). Example 254 (2R)-4-Methyl-2-[[2-[(2-phenoxyethyI)amino]-5-[(phenylmethyl)thio]thiazoIo[4,5- rf]pyrimidin-7-yI]amino]-l-pentanoI MS (APCI) 510 (M+H + , 100%). Example 255 l-[2-[(2-PhenoxyethyI)amino]-5-[(phenylmethyI)thio]thiazoIo[4,5-J]pyrimidin-7-yl]-4- (phenylmethyI)-4-piperidinol. MS (APCI) 584 (M+H + , 100%). Example 256 7-Chloro-N-cycIopropyl-5-[(phenylmethyl)thio]-thiazolo[4,5-d]pyrimidin-2-amine, Prepared by the method of Example 220, using the product of Example 219 and cyclopropan amine. MS (APCI) 351, 349 (M+H + , 100%). NMR δH (d 6 -DMSO) 7.46-7.22 (5H, m), 4.41 (2H, s), 2.85-2.80 (IH, m), 0.90-0.84 (2H, m), 0.71-0.66 (2H, m). Examples 257-260 Example 257 to 260 were prepared by the method of Example 221 using the product of Example 256. Example 257 2-[[2-(CyclopropyIamino)-5-[(phenylmethyl)thio]thiazoIo [4,5-rf]pyrimidin-7- yl]amino] - 1 -butanol MS (APCI) 402 (M+H + , 100%). Example 258 2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo [4,5-rf]pyrimidin-7- yl]amino]- 1 -propanol MS (APCI) 388 (M+KT, 100%). Example 259 (2R)-2-[[2-(Cyclopropylamino)-5-[(phenyImethyI)thio]thiazolo [4,5-- |pyrimidin-7-yl]amino]-4-πιethyl-l-pentanol MS (APCI) 430 (M+H + , 100%). Example 260 /V-[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazoIo[4,5-<fipyrimidin-7-yl]-L- serine, ethyl ester MS (APCI) 446 (M+H + , 100%). Example 261 2-[[7-Chloro-5-[(phenyImethyl)thio]thiazolo[4,5-/ ]pyrimidin-2-yl]amino]-l-pentanol Prepared by the method of Example 231, using the product of Example 219 and 2-amino-l -pentanol. MS (APCI) 397, 395 (M+H + , 100%). ! H NMR (d 6 -DMSO) δ 9.29 (IH, s), 7.46-7.22 (5H, m), 4.93 (IH, t), 4.39 (2H, s), 4.07- 4.00 (IH, m), 3.50 (2H, t), 1.63-1.43 (2H, m), 1.38-1.32 (2H, m), 0.89 (3H, t). Examples 262-264 Example 262 to 264 were prepared by the method of Example 221 using the product of Example 261. Example 262 (2R)-2-[[2-[[l-(HydroxymethyI)butyl]amino]-5-[(phenyImethyl)thio]thiazoIo[4,5- rf]pyrimidin-7-yl]amino]-4-methyI-l-pentanol MS (APCI) 476 (M+H + , 100%). Example 263 N-[2-[[l-(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazoIo[4,5- -/]pyrimidin-7-yl]-L-serine, ethyl ester MS (APCI) 492 (M+H + , 100%). Example 264 (±)-2-[[7-[CycIohexyl(2-hydroxyethyl)amino]-5-[(phenyImethyl)thio]thiazolo[4,5- rf]pyrimidin-2-yl]amino]-l-pentanol MS (APCI) 502 (M+H + , 100%). Examples 265-270 The following examples were prepared by the method of Example 221 , using the product of Example 229. Examples 265 2-[2-[[7-(Ethylamino)-5-[(phenylmethyI)thio]thiazoIo[4,5-J]pyrimidin-2- yl]amino]ethoxy-l-ethanol MS (APCI) 406 (M+H + , 100%). Examples 266 2-[2-[[7-[(l-MethyIethyl)amino]-5-[(phenyImethyl)thio]thiazolo[4,5- ]pyrimidin-2- yl]amino]ethoxy]-l-ethanol MS (APCI) 420 (M+H + , 100%). Examples 267 (±)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- rf]pyrimidin-7-yl]amino]-l-butanol, MS (APCI) 450 (M+H + , 100%). Examples 268 2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazoIo[4,5- d]pyrimidin-7-yl]amino]-2-methyl-l-propanol MS (APCI) 450 (M+H + , 100%). Examples 269 (2R)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazoϊo[4,5- rf]pyrimidin-7-yI]amino]-4-methyI-l-pentanol, MS (APCI) 478 (M+H + , 100%). Examples 270 2-[CycIohexyI-[2-[[2-(2-hydroxyethoxy)ethyl]amino]-5- [(phenylmethyl)thio]thiazoIo[4,5--/]pyrimidin-7-yI]amino]-l-ethanoI MS (APCI) 504 (M+H + , 100%). Examples 271 (±)-2-[[5-[(PhenylmethyI)thio]-2-(4-piperidinylamino)thiazolo[4,5-J]pyrimidin-7- y!]amino]-l-propanol a) 7-Chloro-5-[(phenylmethyl)thio]-N-(4-piperidinyl)-thiazoIo[4,5-rf]pyrimidin-2- amine A solution of the product from Example 219 (0.3g) in tetrahydrofuran (2ml) containing 4- amino-1-piperidinecarboxylic acid, 1,1-dimethylethyl ester (0.161g) and N-ethyldiisopropylamine (0.5 ml) was stirred for 16 hours before evaporating to dryness. The residue was taken into dichloromethane (30ml) and trifluoroacetic acid (3ml) added. The solution was stirred for 30 minutes then concentrated to give the title compound (310mg). MS (APCI) 392 (M+H + , 100%). ΝMR δH (d 6 -DMSO) 9.47 (IH, s), 8.64-8.48 (2H, s), 7.46-7.23 (5H, s), 4.41 (2H, s) 4.21 (IH, s), 3.34 (2H, m), 3.09 (2H, m), 2.18 (2H, m), 1.69 (2H, m). b) (±)-2-[[5-[(PhenylmethyI)thio]-2-(4-piperidinylamino)thiazoIo[4,5-rf]pyrimidin-7- yl]amino]-l-propanol Prepared by the method of Example 221 , using the product of step a). MS (APCI) 431 (M+H + , 100%). Example 272 N-[2-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5 -/]pyrimidin-2-yl]amino]ethyl]- acetamide Prepared according to the method of Example 231 using the product of Example 219. MS (APCI) 396, 394 (M+H + ), 394 (100%). Examples 273-276 Examples 273-276 were prepared by the method of Example 221 using the product of Example 272. Example 273 (±)-N-[2-[[7-[[l-(Hydroxymethyl)propyI]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- rf]pyrimidin-2-yl]amino]ethyl]-acetamide MS (APCI) 447 (M+H + , 100%) Examples 274 (±)-N-[2-[[7-[(2-Hydroxy-l-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- - |pyrimidin-2-yl]amino]ethyl]-acetamide, MS (APCI) 433 (M+H + , 100%) Examples 275 N-[2-[[7-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazoϊo[4,5-rf]pyrimidin-2- yl]amino]ethyl]-acetamide MS (APCI) 419 (M+H + , 100%) Example 276 N-[2-[[7-[[(lR)-l-(HydroxymethyI)-3-methylbutyl]amino]-5- [(phenylmethyl)thio]thiazolo[4,5-f |pyrimidin-2-yI]amino]ethyl]-acetamide, MS (APCI) 475 (M+H + , 100%) Example 277 7-Chloro-5-[(phenylmethyl)thio]-N-[2-(2-thienyl)ethyI]-thiazolo[4,5-</]pyrimidin-2- amine Prepared by the method of Example 231 , using the product of Example 219 and 2-(2-thienyl)ethylamine. MS (APCI), 420, 418 (M+HT), 418 (100%). NMR δH (de-DMSO) 7.45-7.32 (5H, m), 6.96 (2H, m), 4.40 (2H, s), 3.78 (2H, s), 3.16 (2H, t). Examples 278-284 Examples 276 to 284 were prepared by the method of Example 221 using the product of Example 277. Example 278 N 7 -(2-Methoxyethyl)-5-[(phenylmethyI)thio]-N 2 -[2-(2-thienyl)ethyl]thiazolo[4,5- < ]pyrimidine-2,7-diamine MS (APCI) 457 (M+H + , 100%). Example 279 N 7 -(2-EthoxyethyI)-5-[(phenylmethyl)thio]-N 2 -[2-(2-thienyl)ethyl]thiazolo[4,5- d]pyrimidine-2,7-diamine MS (APCI) 471 (M+H + , 100%). Example 280 N 7 -(2,2-DimethyIpropyl)-5-[(phenylmethyl)thio]-N 2 -[2-(2-thienyl)ethyl]thiazolo[4,5- rf]pyrimidine-2,7-diamine MS (APCI) 469 (M+H + , 100%). Example 281 (2R)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazoIo[4,5- rf]pyrimidin-7-yl]amino]- 1-pentanol MS (APCI) 499 (M+H + , 100%). Example 282 (±)-l-[[5-[(PhenylmethyI)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-rf]pyrimidin- 7-yl]amino]- 2-propanol MS (APCI) 457 (M+H + , 100%). Example 283 (±)-2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-J]pyrimidin- 7-yl]amino]- 1 -butanol MS (APCI) 471 (M+H + , 100%). Example 284 (±)-2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyI]amino]thiazolo[4,5-d]pyrimidin- 7-yI]amino]- 1-propanol MS (APCI) 457 (M+H + , 100%). Example 285 2-[[7-Chloro-5-[(phenyImethyl)thio]thiazolo[4,5-rf]pyrimidin-2-yI]amino]-l-ethanol Prepared by the method of Example 231, using the product of Example 219 and 2-aminoethanol. MS (APCI) 355, 353 (M+H + ), 353 (100%). NMR δH (d 6 -DMSO) 9.48 (IH, s), 7.45-7.30 (5H, m), 4.95 (IH, t), 4.40 (2H, s), 3.60 (4H, m). Examples 286-287 Examples 286 to 287 were prepared by the method of Example 221 using the product of Example 285. Example 286 (2R)-2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin- 7-y l]amino] -4-methyI- 1 -pentanol MS (APCI) 433 (M+H + , 100%). Example 287 (±)-NΛ-Diethyl-l-[2-[(2-hydroxyethyI)amino]-5-[(phenyImethyl)thio]thiazolo[4,5- < /]pyrimidin-7-yI]-3-piperidinecarboxamide MS (APCI) 500 (M+H + , 100%). Example 288 3-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-έ/]pyrimidin-2-yI]amino]-l-propanol Prepared by the method of Example 231, using the product of Example 219 and 3- aminopropanol. MS (APCI) 369, 367 (M+H + ), 367 (100%). NMR δH (d 6 -DMSO) 9.36 (IH, s), 7.43-7.27 (5H, m), 4.57 (IH, t), 4.40 (2H, s), 3.49 (4H, m), 1.75 (2H, m). Examples 289-291 Examples 289-291 were prepared by the method of Example 221 using the product of Example 288. Example 289 (2R)-2-[[2-[(3-Hydroxypropyl)amino]-5-[( phenylmethyI)thio]thiazolo[4,5- rf]pyrimidin-7-yl]amino]-4-methyl-l-pentanol MS (APCI) 447 (M+H + , 100%). Example 290 (±)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin- 7-yl]amino]-l-butanoI MS (APCI) 419 (M+H + , 100%). Example 291 (±)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazoIo[4,5-rf]pyrimidin- 7-yI]amino]-l-propanoI MS (APCI) 405 (M+H + , 100%) Example 292 2-[[7-Chloro-5-[(phenylmethyl)thio]thiazolo[4,5-dGpyrimidin-2-yl]amino]-acetamide Prepared by the method of Example 231 , using the product of Example 219 and glycinamide hydrochloride. MS (APCI) 368, 66 (M+H + ), 366 (100%). NMR δH (de-DMSO) 7.61 (IH, s), 7.45-7.24 (6H, ), 4.40 (2H, s), 4.14-4.12 (2H, m), 9.57 (lH, s). Example 293 2-[[7-[(2-Hydroxy-l-methyIethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- d]pyrimidin-2-yl]amino-acetamide Prepared according to the method of Example 221 using the product of Example 292. MS (APCI) 404 (M+H + , 100%). Example 294 4-[[7-ChIoro-5-[(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-2-yl]-3-azetidinyl]-l- piperazinesulfonamide Prepared by the method of Example 231, using the product of Example 219 and 3-azetidinyl- 1 -piperazinesulfonamide. MS (APCI), 512, 514 (M+H + ), 512 (100%). NMR δH (d 6 -DMSO) 7.69-7.22 (5H, m), 6.80 (2H, s), 4.40 (2H, s), 4.34-4.12 (4H, m), 3.56-3.50 (IH, m), 3.40 (4H, s), 3.00 (4H, s). Example 295 4-[l-[7-[(4-MethyIcycIohexyl)amino]-5-[(phenylmethyI)thio]thiazoIo[4,5-rf]pyrimidin- 2-yl] -3-azetidinyl] -1 -piperazinesulfonamide, Prepared by the method of Example 221, using the product of Example 294. MS (APCI) 588 (M+H + , 100%). Example 296 7-Chloro-N-[[2-(4-morpholinyI)ethyl]-5-[(phenylmethyl)thio]-thiazolo[4,5- d]pyrimidin-2-amine Prepared by the method of Example 231, using the product of Example 219 and 2-(4-morpholinyl)ethyl] amine. MS (APCI) 424, 422 (M+H + ), 422 (100%). NMR δH (d 6 -DMSO) 9.34 (IH, s), 7.68-7.23 (5H, m), 4.40 (2H, s), 3.59-3.56 (6H, m), 2.54 (2H, t), 2.44-2.41 (4H, m). Examples 297-300 Examples 297-300 were prepared according to the method of Example 221 using the product of Example 296. Example 297 3-[[2-[[2-(4-MorphoIinyl)ethyI]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- d]pyrimidin-7-yl]amino]-l-propanol MS (APCI) 460 (M+H + , 100%). Example 298 2-Methyl-2-[[2-[[2-(4-morphoIinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- rf]pyrimidin-7-yl]amino]-l-propanol MS (APCI) 464 (M+H + , 100%). Example 299 (±)-2-[[2-[[2-(4-MorphoIinyl)ethyl]amino]-5-[(phenyImethyl)thio]thiazolo[4,5- rf]pyrimidin-7-yl]amino]-l-propanol MS (APCI) 460 (M+H + , 100%). Example 300 (2R)-4-MethyI-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5- [(phenylmethyl)thio]thiazolo[4,5--f]pyrimidin-7-yl]amino]-l-pentanoI MS (APCI) 502 (M+H + , 100%). Examples 301-302 Examples 301-302 were prepared by the method of Example 12 using the product of Example 140. Example 301 2-[[2-(3,4-Dihydroxyphenyl)ethyl]amino]-5-[(phenylmethyI)thio]-thiazoIo[4,5- rf]pyrimidin-7(4/7)-one MS (APCI) 427 (M+H + , 100%). Example 302 (±)-2-[(2-Hydroxy-l-methylethyI)amino]-5-[(phenylmethyl)thio]-thiazoIo[4,5- έ/]pyrimidin-7(4fl r )-one MS (APCI) 349 (M+H + , 100%). Pharmacological Data Ligand Binding Assay [ 125 rjlL-8 (human, recombinant) was purchased from Amersharn, U.K. with a specific activity of 2,000Ci/mmol. All other chemicals were of analytical grade. High levels of hrCXCR2 were expressed in HEK 293 cells (human embryo kidney 293 cells ECACC No. 85120602) (Lee et al. (1992) /. Biol. Chem. 267 pp 16283- 16291). hrCXCR2 cDNA was amplified and cloned from human neutrophil mRNA. The DNA was cloned into PCRScript (Stratagene) and clones were identified using DNA. The coding sequence was sub-cloned into the eukaryotic expression vector RcCMV (Invitrogen). Plasmid DNA was prepared using Quiagen Megaprep 2500 and transfected into HEK 293 cells using Lipofectamine reagent (Gibco BRL). Cells of the highest expressing clone were harvested in phosphate- buffered saline containing 0.2%(w/v) ethylenediaminetetraacetic acid (EDTA) and centrifuged (200g, 5min.). The cell pellet was resuspended in ice cold homogenisation buffer [lOmM HEPES (pH 7.4), ImM dithiothreitol, ImM EDTA and a panel of protease inhibitors (ImM phenyl methyl sulphonyl fluoride, 2μg/ml soybean trypsin inhibitor, 3mM benzamidine, 0.5μg/ml leupeptin and lOOμg/ml bacitracin)] and the cells left to swell for 10 minutes. The cell preparation was disrupted using a hand held glass mortar/PTFE pestle homogeniser and cell membranes harvested by centrifugation (45 minutes, 100,000g, 4°C). The membrane preparation was stored at -70°C in homogenisation buffer supplemented with Tyrode's salt solution (137mM NaCl, 2.7mM KC1, 0.4mM NaH 2 PO 4 ), 0.1%(w/v) gelatin and 10%(v/v) glycerol. All assays were performed in a 96-well MultiScreen 0.45μm filtration plates (Millipore, U.K.). Each assay contained ~50pM [ 125 I]IL-8 and membranes (equivalent to -200,000 cells) in assay buffer [Tyrode's salt solution supplemented with lOmM HEPES (pH 7.4), 1.8mM CaCl 2 , ImM MgCl 2 , 0.125mg/ml bacitracin and 0.1%(w/v) gelatin]. In addition, a compound of formula (I) according to the Examples was pre-dissolved in DMSO and added to reach a final concentration of l%(v/v) DMSO. The assay was initiated with the addition of membranes and after 1.5 hours at room temperature the membranes were harvested by filtration using a Millipore MultiScreen vacuum manifold and washed twice with assay buffer (without bacitracin). The backing plate was removed from the MultiScreen plate assembly, the filters dried at room temperature, punched out and then counted on a Cobra γ-counter. The compounds of formula (I) according to the Examples were found to have IC50 values of less than (<) lOμM. Intracellular Calcium Mobilisation Assay Human neutrophils were prepared from EDTA-treated peripheral blood, as previously described (Baly et al. (1997) Methods in Enzymology 287 pp70-72), in storage buffer [Tyrode's salt solution (137mM NaCl, 2.7mM KC1, 0.4mM NaH 2 PO 4 ) supplemented with 5.7mM glucose and lOmM HEPES (pH 7.4)]. The chemokine GROα (human, recombinant) was purchased from R&D Systems (Abingdon, U.K.). All other chemicals were of analytical grade. Changes in intracellular free calcium were measured fluorometrically by loading neutrophils with the calcium sensitive fluorescent dye, fluo-3, as described previously (Merritt et al. (1990) Biochem. J. 269, pp513-519). Cells were loaded for 1 hour at 37°C in loading buffer (storage buffer with 0.1%(w/v) gelatin) containing 5μM fluo-3 AM ester, washed with loading buffer and then resuspended in Tyrode's salt solution supplemented with 5.7mM glucose, 0.1%(w/v) bovine serum albumin (BSA), 1.8mM CaCl 2 and ImM MgCl 2 . The cells were pipetted into black walled, clear bottom, 96 well micro plates (Costar, Boston, U.S.A.) and centrifuged (200g, 5 minutes, room temperature). A compound of formula (I) according to the Examples was pre-dissolved in DMSO and added to a final concentration of 0.1%(v/v) DMSO. Assays were initiated by the addition of an A 50 concentration of GROα and the transient increase in fluo-3 fluorescence (λ_ =490nm and λ Em = 520nm) monitored using a FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.). The compounds of formula (I) according to the Examples were tested and found to be antagonists of the CXCR2 receptor in human neutrophils.

Claims: C L A I M S 1. A compound of general formula wherein R 1 represents a hydrogen atom, or a group -NR 3 R 4 ; 3 4 R and R each independently represent a hydrogen atom, or a 4-piperidinyl, C3-C6 cycloalkyl or -Cg alkyl group, which latter two groups may be optionally substituted by one or more substituent groups independently selected from halogen atoms and -NR R , -CONR 5 R 6 , -OR 7 , -COOR 7 , -NR 8 COR 9 , -SR 10 , -SO 2 R 10 , -SO 2 NR 5 R 6 , -NR 8 SO 2 R 9 , moφholinyl, -C4 alkyl, C3-C6 cycloalkyl, tetrahydrofuranyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, -NR R , -CONR R , - OR 7 , -NR 8 COR 9 , -SO 2 NR 5 R 6 , -NR 8 SO 2 R 9 , Cι-C 6 alkyl and trifluoromethyl groups, 3 4 or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one or more substituent groups independently selected from -NR 5 R 6 , -CONR 5 R 6 , -OR 7 , -COOR 10 , -NR 8 COR 9 , and Cι-C 6 alkyl optionally substituted by one or more substituents independently selected from halogen atoms and 11 12 7 -NR R and -OR groups; 13 14 X represents a group -OH or -NR R ; 13 14 R and R each independently represent a hydrogen atom, a 4-piperidinyl group optionally substituted by a C1-C4 alkylphenyl substituent group, or a C3-C7 carbocyclic, C1-C8 alkyl, C 2 -Cό alkenyl or C 2 -Cό alkynyl group, which latter four groups may be optionally substituted by one or more substituent groups independently selected from halogen atoms and -NR 5 R 6 , -CONR 5 R 6 , -OR 7 , -COOR 7 , -NR 8 COR 9 , -SR 1 -SO 2 R 10 -SO 2 NR 5 R 6 , -NR 8 SO 2 R 9 , moφholinyl, C r C 4 alkyl, C 3 -C 6 cycloalkyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, -NR 5 R 6 , -CONR 5 R 6 , -OR 7 , -NR 8 COR 9 , -SO 2 NR 5 R 6 , NR 8 SO 2 R 9 Cι-C 6 alkyl and trifluoromethyl groups, 13 14 or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one or more substituent groups independently selected from -NR R , -CONR 5 R 6 , -OR 7 , -COOR 7 , -NR 8 COR 9 , and Cι-C 6 alkyl optionally substituted by one 11 12 or more substituents independently selected from halogen atoms and phenyl, -NR R 7 and -OR groups; R alkyl or C 2 -Cό alkenyl group optionally substituted by a phenyl or phenoxy group, wherein the phenyl or phenoxy group may itself be optionally substituted by one or more substituents independently selected from halogen atoms and nitro, Cι-C 6 alkyl, trifluoromethyl, -OR 7 , -C(O)R 7 , -SR 10 , -NR 15 R 16 and phenyl groups; R and R each independently represent a hydrogen atom or a Cj-Cg alkyl or phenyl group, each of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, -OR and -NR R , or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system optionally comprising a further heteroatom selected from oxygen and nitrogen atoms, which ring system may be optionally substituted 17 by one or more substituent groups independently selected from phenyl, -OR -COOR 17 , -NR 15 R 16 , -CONR 15 R 16 , -NR 15 COR 16 , -SONR 15 R 16 , and Cι-C 6 alkyl optionally substituted by one or more substituents independently selected from halogen atoms and -NR R and -OR groups; 7 9 R and R each independently represent a hydrogen atom or a C -Cβ alkyl or phenyl group, each of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, -OR and -NR R ; and each of R , R , R , R , R , R and R independently represents a hydrogen atom or a Ci-Cg alkyl or phenyl group; with the proviso that when R and X both represent -NH 2 , 2 then R does not represent a methyl group; or a pharmaceutically acceptable salt or solvate thereof. 2. A compound according to claim 1 , wherein R represents a group -NR R . 3 4 3. A compound according to claim 1 or claim 2, wherein R and R each independently represent a hydrogen atom, or a 4-piperidinyl, C3-C6 cycloalkyl or -C Q alkyl group, which latter two groups may be optionally substituted by one, two, three or four substituent groups independently selected from halogen atoms and -NR R , -CONR R , -OR , -COOR 7 , -NR 8 COR 9 , -SR 10 , -SO 2 R 10 , -SO 2 NR 5 R 6 , -NR 8 SO 2 R 9 , moφholinyl, C1-C4 alkyl, C3-C6 cycloalkyl, tetrahydrofuranyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one, two, three or four substituents independently selected from halogen atoms and cyano, nitro, -NR R , -CONR R , -OR 7 , -NR 8 COR 9 , -SO 2 NR 5 R 6 , -NR 8 SO 2 R 9 , C1-C4 alkyl and trifluoromethyl groups. 2 4. A compound according to any one of claims 1 to 3, wherein R represents a -C6 alkyl or C 2 -C6 alkenyl group optionally substituted by a phenyl or phenoxy group, wherein the phenyl or phenoxy group may itself be optionally substituted by one, two, three or four substituents independently selected from halogen atoms and nitro, -C4 alkyl, trifluoromethyl, -OR 7 , -C(O)R 7 , -SR 10 , -NR 15 R 16 and phenyl. O 00/09511 "^ 129 5. A compound according to any one of the preceding claims, wherein X represents 13 14 13 14 -NR R and R and R each independently represent a hydrogen atom, a 4-piperidinyl group optionally substituted by a C1-C4 alkylphenyl substituent group, or a C3-C7 carbocyclic, Cj-Cg alkyl, C2-C6 alkenyl or C 2 -C6 alkynyl group, which latter four groups may be optionally substituted by one, two, three or four substituent groups independently selected from halogen atoms and -NR 5 R 6 , -CONR 5 R 6 , -OR 7 , -COOR 7 , -NR 8 COR 9 , -SR 10 -SO 2 R 10 , -SO 2 NR 5 R 6 , -NR 8 SO 2 R 9 , moφholinyl, C 1 -C4 alkyl, C3-C6 cycloalkyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one, two, three or four substituents independently selected from halogen atoms and cyano, nitro, -NR 5 R 6 , -CONR 5 R 6 , -OR 7 , -NR 8 COR 9 , -SO 2 NR 5 R 6 , 8 9 NR SO 2 R , C1-C4 alkyl and trifluoromethyl groups. 6. A compound according to claim 1 being selected from: (2R)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-<i]pyrimidin-7-yl]amino]- 1 -butanol, (S)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5- lpyrimidin-7-yl]amino]-l-butanol, 2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-<flpyrimidin-7(4H)-one, 5-[[(3-Phenoxyphenyl)methyl]thio]thiazolo[4,5- r ]pyrimidin-7(4H)-one, 2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7(4H)-one, (±)-2-[[2-Amino-5-(pentylthio)thiazolo[4,5-<fIpyrimidin-7-yl]amino]- 1 -butanol, 2-[[2-Amino-5-(pentylthio)thiazolo[4,5-(i]pyrimidin-7-yl]amino]ethanol, 5-(Pentylthio)thiazolo[4,5-^pyrimidin-7(4H)-one, 2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-ύf]pyrimidin-7(4H)-one, 2-Amino-5-(pentylthio)thiazolo[4,5-<f]pyrimidin-7(4H)-one, 2-[[3-(Dimethylamino)propyl]amino]-5-(pentylthio)thiazolo[4,5-< ]pyrimidin-7(4H)-one, 2-[[2-(Diethylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5--/Ipyrimidin-7(4H)-one, 2-[[2-(Dimethylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5-ύ?]pyrimidin-7(4H)-one, 2-[(3-Hydroxypropyl)amino]-5-(pentylthio)thiazolo[4,5- ]pyrimidin-7(4H)-one, 2-[[2-(Acetylamino)ethyl]amino]-5-(pentylthio)thiazolo[4,5- ]pyrimidin-7(4H)-one, (±)-2-[(2,3-Dihydoxypropyl)amino]-5-(pentylthio)thiazolo[4,5-<fjpyrimidin-7(4H)-one, 2-[[2-(4-Mθφholinyl)ethyl]amino]-5-(pentylthio)thiazolo[4,5-<f|pyrimidin-7(4H)-one, 2-[(2-Methoxyethyl)amino]-5-(pentylthio)thiazolo[4,5-<i]pyrimidin-7(4H)-one, 2-[(l-Methylethyl)amino]-5-(pentylthio)thiazolo[4,5-cf|pyrimidin-7(4H)-one, 2-(Cyclopropylamino)-5-(pentylthio)thiazolo[4,5-<f]pyrimidin-7(4H)-one, (±)-2-[(2-Ηydoxypropyl)amino]-5-(pentylthio)thiazolo[4,5-<i]pyrimidin-7(4H)-one, 2-[[2-(2-Ηydroxyethoxy)ethyl]amino]-5-(pentylthio)thiazolo[4,5--flpyrimidin-7(4H)-one, 2-[(2-Ηydroxy-2-methylpropyl)amino]-5-(pentylthio)thiazolo[4,5-<i]pyrimidin-7(4H)-one, 2-[(2-Ηydroxyethyl)amino]-5-(pentylthio)thiazolo[4,5-< |pyrimidin-7(4H)-one, (2S,3R)-3-Ηydroxy-2-[(7-oxo-5-(pentylthio)-4H-thiazolo[4,5-ύπpyrimidin-2-yl]- amino)butanamide, N 7 -[3-(Dimethylamino)propyl]-5-(pentylthio)thiazolo[4,5-(i]pyrimidine-2,7-diamine, N 7 -[2-(Diethylamino)ethyl]-5-(pentylthio)thiazolo[4,5-ύT]pyrimidine-2,7-diamine, N 7 -[2-(Dimethylamino)ethyl]-5-(pentylthio)thiazolo[4,5- |pyrimidine-2,7-diamine, 3-[(2-Amino-5-(pentylthio)thiazolo[4,5-cTlpyrimidin-7-yl)amino]-l-propanol, N 7 -Cyclohexyl-5-(pentylthio)thiazolo[4,5-^pyrimidine-2,7-diamine, (±)-3-[(2-Amino-5-((phenylmethyl)thio)thiazolo[4,5- /]pyrimidin-7-yl)amino]-l,2- propanediol, N 7 -(2-Methoxyethyl)-5-(pentylthio)thiazolo[4,5- ]pyrimidine-2,7-diamine, 5-(Pentylthio)-N 7 -propylthiazolo[4,5- ]pyrimidine-2,7-diamine, N 7 -Cyclopentyl-5-(pentylthio)thiazolo[4,5-if|pyrimidine-2,7-diamine, N 7 -Cyclopropyl-5-(pentylthio)thiazolo[4,5-<i]pyrimidine-2,7-diamine, N 7 -(2-Methylpropyl)-5-(pentylthio)thiazolo[4,5--i]pyrimidine-2,7-diamine, (±)-l-[(2-Amino-5-(pentylthio)thiazolo[4,5- ]pyrimidin-7-yl)amino]-2-propanol, (exo)-N 7 -Bicyclo[2.2.1]hept-2-yl-5-(pentylthio)thiazolo[4,5-cT|pyrimidine-2,7-diamine, 2-[2-[[2-Amino-5-(pentylthio)thiazolo[4,5-< lpyrimidin-7-yl]amino]ethoxy]ethanol, (±)-N 7 -(2-Methylbutyl)-5-(pentylthio)thiazolo[4,5-£ ]pyrimidine-2,7-diamine, l-[[2-Amino-5-(pentylthio)thiazolo[4,5-< lpyrimidin-7-yl]amino]-2-methyl-2-propanol, N 7 -[(2-Aminophenyl)methyl]-5-(pentylthio)thiazolo[4,5--i]pyrimidine-2,7-diamine, 2-Amino-5-[(2-phenoxyethyl)thio]thiazolo[4,5-d]pyrimidin-7(4H)-one, (E)-2-Amino-5-[(3-phenyl-2-propenyl)thio]thiazolo[4,5--i]pyrimidin-7(4H)-one, -Amino-5-[[3-[2,4-bis(l,l-dimethylethyl)phenoxy]propyl]thio]thiazolo[4,5-£T|pyrimidin- (4H)-one, -Amino-5-[[[(4-trifluoromethyl)phenyl]methyl]thio]thiazolo[4,5-< ]pyrimidin-7(4H)-one, -Amino-5-[[(3,5-dichlorophenyl)methyl]thio]thiazolo[4,5-<f]pyrimidin-7(4H)-one, -Amino-5-[[(2,4-dichlorophenyl)methyl]thio]thiazolo[4,5--i]pyrimidin-7(4H)-one, -Amino-5-[[(3,4-dichlorophenyl)methyl]thio]thiazolo[4,5-ύT|pyrimidin-7(4H)-one, -Amino-5-[[(3,5-dibromophenyl)methyl]thio]thiazolo[4,5-(i]pyrimidin-7(4H)-one, -Amino-5-[[(2-nitrophenyl)methyl]thio]thiazolo[4,5-<fjpyrimidin-7(4H)-one, 2-Amino-5-[[(2-fluorophenyl)methyl]thio]thiazolo[4,5-cT|pyrimidin-7(4H)-one, 2-Amino-5-[[(2-iodophenyl)methyl]thio]thiazolo[4,5--fIpyrimidin-7(4H)-one, 2-Amino-5-[[(3-chlorophenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7(4H)-one, 2-Amino-5-[[(2-chlorophenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7(4H)-one, 2-Amino-5-[[(4-chloro-2-nitrophenyl)methyl]thio]thiazolo[4,5-(i]pyrimidin-7(4H)-one, 2-Amino-5-[[(3-chloro-4-methoxyphenyl)methyl]thio]thiazolo[4,5-cT]pyrimidin-7(4H)-one, 2-Amino-5-[[(2,3-dichlorophenyl)methyl]thio]thiazolo[4,5-i Ipyrimidin-7(4H)-one, 2-Amino-5-[[(3,5-difluorophenyl)methyl]thio]thiazolo[4,5--fIpyrimidin-7(4H)-one, 2-Amino-5-[[[(2,4-bis(trifluoromethyl)phenyl]methyl]thio]thiazolo[4,5--i]pyrimidin-7(4H)- one, 2-Amino-5-[[(2-bromophenyl)methyl]thio]thiazolo[4,5-( lpyrimidin-7(4H)-one, 2-Amino-5-[[(2,3,4-trifluorophenyl)methyl]thio]thiazolo[4,5-(i]pyrimidin-7(4H)-one, 2-Amino-5-[[(3-bromophenyl)methyl]thio]thiazolo[4,5--fIpyrimidin-7(4H)-one, 2-Amino-5-[[(2-fluoro-3-methylphenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7(4H)-one, 3-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]-2,2-dimethyl-l- propanol, (±)-α-[[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-cT|pyrimidin-7- yl]amino]methyl]benzenemethanol, (R)-β-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7- yl] amino]benzenepropanol , 2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-(flpyrimidin-7-yl]amino]ethanol, (2R)-2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-(i]pyrimidin-7-yl]amino]4- methylpentanol, (±)-l-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5--i]pyrimidin-7-yl]amino]-2-propanol, (±)-β-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]-4- chlorobenzenepropanol, (±)-3-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-<i]pyrimidin-7-yl]amino]-l,2- propanediol, 2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5- lpyrimidin-7-yl]propylamino]ethanol, (±)-l-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-- ]pyrimidin-7-yl]-3-pyrrolidinol, (±)- 1 -[2- Amino-5-[(phenylmethyl)thio]thiazolo[4,5--i]pyrimidin-7-yl]-3-piperidinol, l-[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5-ii]pyrimidin-7-yl]-4-piperidinol, 3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-( |pyrimidin-7-yl]amino]-2,2- dimethyl- 1 -propanol, (±)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-- ]pyrimidin-7-yl]amino]- 1 -butanol, (±)-α-[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-cTlpyrimidin-7-yl]- amino]methyl]benzenemethanol, 4-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7-yl]amino]-l- butanol, 6-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5--i]pyrimidin-7-yl]amino]-l- hexanol, 4-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5--i]pyrimidin-7-yl]- amino]cyclohexanol, (R)-β-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5--/]pyrimidin-7-yl]- amino]benzenepropanol, (±)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]- 1 -propanol, 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-^pyrimidin-7-yl]- amino]ethanol, (2R)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7-yl]- amino] -4-methylpentanol , (±)-l-Amino-3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]-2-propanol, (±)-l-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-cflpyrimidin-7-yl]amino]- 2-propanol, 2-[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7- yl]amino]methyl]-2-ethyl-l,3-propanediol, (±)-β-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7-yl]amino]- 4-chlorobenzenepropanol, (±)-3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-< ]pyrimidin-7-yl]amino]- 1,2-propanediol, 2-[[2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-7- yl]amino]ethyl]amino]ethanol, 3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-- Ipyrimidin-7-yl]amino]-l- propanol, (±)-α-[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]methyl]-3,4-dichlorobenzenepropanol, l-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-^]pyrimidin-7-yl]amino]-2- methyl-2-propanoI, 2-[2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7- yl ] amino] ethoxy] ethanol , 5-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5--i]pyrimidin-7-yl]amino]-l- pentanol, (2S)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7- yl] amino] -4-(methylthio)- 1 -butanol, 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-cf]pyrimidin-7- yl]butylamino]ethanol, 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-(i]pyrimidin-7- yl]propylamino]ethanol, 2,2'-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7- yl]imino]bisethanol, 2-[[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-< ]pyrimidin-7-yl]-(2- hydroxyethyl)amino]methyl]phenol, 3-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-- |pyrimidin-7-yl]-(2- hydroxyethyl)amino]- 1 -propanol, (±)-l-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-ύripyrimidin-7-yl]-3- pyrrolidinol, (tran^)-l-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-cf]pyrimidin-7-yl]-4- hydroxy-L-proline phenylmethyl ester, (±)-l-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-ci]pyrimidin-7-yl]-3- piperidinemethanol, (±)-l-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-ύ pyrimidin-7-yl]-3- piperidinol, (2S)-l-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-< |pyrimidin-7-yl]-2- pyrrolidinemethanol, l-[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-< |pyrimidin-7-yl]-4- piperidinol, (2R)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5- lpyrimidin-7- yl]amino]-l -butanol, (2S)-2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5--i]pyrimidin-7- yl] amino] - 1 -butanol, (2R)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-i]pyrimidin-7- yl]amino]- 1 -butanol, 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7-yl]amino]-l,3- propanediol, 2-[[2-Amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2- methyl- 1 -propanol, 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7-yl]amino]-2- methyl- 1-propanol, l-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-- |pyrimidin-7-yl]amino]-2- methyl-2-propanol, 5-[[(2,3-Difluorophenyl)methyl]thio]-N 7 -(2-fluoroethyl)thiazolo[4,5- ]pyrimidine-2,7- diamine, (7R-trα«5 , ) 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-ύTIpyrimidin-7- yl] amino] -cyclopentanol , (7S-tr «^) 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]-cyclopentanol, 2-[[2-Amino-5-[(phenylmethyl)thio]thiazolo[4,5- lpyrimidin-7-yl]amino]-2-methyl-l- propanol, 2-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-- |pyrimidin-7- yl]amino]- 1 -propanol, 2-[[2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(phenylmethyl)amino]thiazolo[4,5- < i]pyrimidin-7-yl] amino] -2-methyl- 1 -propanol, 5-[[(2,3-Difluorophenyl)methyl]thio]thiazolo[4,5-cT|pyrimidin-7(4H)-one, (±)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-i]pyrimidin-7- yl] amino] - 1 -butanol , (lS,2S)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7- yl] amino] -cyclohexanol, (±)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5--f|pyrimidin-7- yl]amino]- 1 -propanol, 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5- |pyrimidin-7-yl]amino]-l- ethanol, (2R)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-< ]pyrimidin-7- yl]amino]-4-methyl- 1 -pentanol, (±)-l-[[2-Armno-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-<i]pyrimidin-7- yl]amino]-2-propanol, 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-( ]pyrimidin-7-yl]amino]-2- methyl- 1 ,3-propanediol, l-[[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-ύT]pyrimidin-7- yl]amino]methyl]-cyclohexanol, (2R)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]-l -butanol, 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7-yl]-(2- aminoethyl)amino]~ 1 -ethanol, 2-[2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-- ]pyrimidin-7- yl] amino]ethoxy] - 1 -ethanol, (αS)-α-[(lR)-l-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-c ]pyrimidin- 7-yl]methylamino]ethyl]-benzenemethanol, l-[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-(i]pyrimidin-7-yl]-4- piperidinol, 5-[[(2,3-Difluorophenyl)methyl]thio]-N 7 -ethyl-thiazolo[4,5-i/]pyrimidine-2,7-diamine, 5-[[(2,3-Difluorophenyl)methyl]thio]-N 7 -(2-propenyl)-thiazolo[4,5- ]pyrimidine-2,7- diamine, (lS,2S)-2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-< Ipyrirnidin-7- yl]amino]-l-phenyl-l,3-propanediol, 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-ύf]pyrimidin-7-yl]amino]- 1,3-propanediol, 2-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-cT|pyrimidin-7-yl]amino]-l- ethanol, (±)-5-[[(2,3-Difluorophenyl)methyl]thio]-N 7 -(2-methoxy-l-methylethyl)-thiazolo[4,5- ]pyrimidine-2,7-diamine, N 7 -Cyclopropyl-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5-cTIpyrimidine-2,7- diamine, (±)-2-[[2-Amino-5-[[(2,3-difluoroρhenyl)methyl]thio]-thiazolo[4,5- |pyrimidin-7- yl] amino] - 1 -propanol , 4-[[2-Amino-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5- ]pyrimidin-7-yl]amino]-l- butanol, 5-[[(2,3-Difluoroρhenyl)methyl]thio]-N 7 -[2-(lH-imidazol-4-yl)ethyl]-thiazolo[4,5- < |pyrimidine-2,7-diamine, (±)-N-[5-[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-l,l- dimethylethyl)amino]thiazolo[4,5-<i]pyrimidin-2-yl]-serine, methyl ester, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(l-methylethyl)amino]thiazolo[4,5- cT|pyrimidin-7-yl]amino]-2-methyl- 1 -propanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-(ethylamino)thiazolo[4,5-<i]pyrimidin-7- yl]amino]-2-methyl- 1 -propanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(lH-indol-3-yl)ethyl]amino]thiazolo[4,5- < f]pyrimidin-7-yl] amino] -2-methyl- 1-propanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(l-naphthalenylmethyl)amino]thiazolo[4,5- i]pyrimidin-7-yl]amino]-2-methyl- 1 -propanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(l,2-diphenylethyl)amino]thiazolo[4,5- < i]pyrimidin-7-yl]amino]-2-methyl-l-propanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(2,2,2-trifluoroethyl)amino]thiazolo[4,5- uT]pyrimidin-7-yl]amino]-2-methyl-l-propanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[(3,4,5- trimethoxyphenyl)methyl]amino]thiazolo[4,5-<i]pyrimidin-7-yl]amino]-2-methyl-l- propanol, ?-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(l,l-dimethylethyl)amino]thiazolo[4,5- <i]pyrimidin-7-yl]amino]-2-methyl- 1-propanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5- ( |pyrimidin-7-yl]amino]-2-methyl- 1 -propanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(4-methylcyclohexyl)amino]thiazolo[4,5- <i]pyrimidin-7-yl]amino]-2-methyl-l-propanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-l,l- dimethylethyl)amino]thiazolo[4,5-<i]pyrimidin-2-yl]amino]-acetamide, 2-[[2-[[2-(4-Aminophenyl)ethyl]amino]-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5- ^pyrimidin-7-yl]amino]-2-methyl- 1-propanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5- ύ?]pyrimidin-7-yl]amino]-2-methyl- 1 -propanol, 2-[[2-(Cyclopropylamino)-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5- ]pyrimidin-7- yl] amino] -2-methyl- 1-propanol, (±)-2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-7-[(2-hydroxy-l,l- dimethylethyl)amino]thiazolo[4,5-cf]pyrimidin-2-yl]amino]-l-pentanol, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2- hydroxyethoxy)ethyl]amino]thiazolo[4,5-i]pyrimidin-7-yl]amino]-2-methyl-l-propanol, N-[5-[[(2,3-Difluorophenyl)methyl]thio]-6,7-dihydro-7-oxo-thiazolo[4,5-<i]pyrimidin-2- yl]-DL-serine, methyl ester, 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(l-methylethyl)amino]-thiazolo[4,5-<2Tlpyrimidin- 7(4H)-one, 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(lH-indol-3-yl)ethyl]amino]-thiazolo[4,5- ύT]pyrimidin-7(4H)-one, 2-[[5-[[(2,3-Difluorophenyl)methyl]thio]-6,7-dihydro-7-oxo-thiazolo[4,5--i]pyrimidin-2- yl] amino]-acetamide, 2-[[2-(4-Aminophenyl)ethyl]amino]-5-[[(2,3-difluorophenyl)methyl]thio]-thiazolo[4,5- d]pyrimidin~7(4H)-one, 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]-thiazolo[4,5--i]pyrimidin- 7(4H)-one, 5-[[(2,3-Difluorophenyl)methyl]thio]-2-[[2-(2-hydroxyethoxy)ethyl]amino]-thiazolo[4,5- < |pyrimidin-7(4H)-one, 2-[[2-(Cyclohexylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-(i]pyrimidin-7-yl]amino]-2- methyl- 1 -propanol, 2-[[2-[(l,l-Dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-(i]pyrimidin-7- yl]amino]-2-methyl- 1 -propanol, N-[7-[(2-Ηydroxy- 1 , 1 -dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- cT]pyrimidin-2-yl]-DL-alanine, methyl ester, 4-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ( |pyrimidin-2-yl]amino]-cyclohexanol, 2-Methyl-2-[[2-[(4-phenylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-^]pyrimidin-7- yl]amino]- 1 -propanol, 2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5- ]pyrimidin-7-yl]amino]- 1-propanol, 2-Methyl-2-[[2-[(l-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]- 1-propanol, 2-[[2-[[2-(4-Aminophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]-2-methyl- 1 -propanol, N-[7-[(2-Hydroxy- 1 , 1 -dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- < i]pyrimidin-2-yl]-L-valine, ethyl ester, (2S)-2-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyri mi din-2-yl]amino]-4-methyl-pentan amide, 2-Methyl-2-[[2-[(2-phenylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-<i]pyrimidin-7- yl]amino]- 1 -propanol, 2-[[2-[[(4-Aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl] amino] -2-methyl- 1 -propanol, 2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5- ]pyrimidin-7-yl]amino]- 1 -propanol, 2-[[2-[(2-Fluoroethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-ύ ]pyrimidin-7-yl]amino]- 2-methyl- 1 -propanol , 2-Methyl-2-[[2-[[(3-nitrophenyl)methyl]amino]-5-[(ρhenylmethyl)thio]thiazolo[4,5- <f]pyrimidin-7-yl]amino]-l-propanol, (α/?)-α-[( 1 S)- 1 -[[7-[(2-Hydroxy- 1 , 1 -dimethylethyl)amino]-5- [(phenylmethyl)thio]thiazolo[4,5-ύT|pyrimidin-2-yl]amino]ethyl]-benzenemethanol, 2-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[(3,4,5- trimethoxyphenyl)methyl]amino]thiazolo[4,5-< |pyrimidin-7-yl]amino]- 1-propanol, 2-Methyl-2-[[2-[(lR-trans)-(2-phenylcyclopropyl)amino]-5- [(phenylmethyl)thio]thiazolo[4,5-^pyrimidin-7-yl]amino]-l-propanol, 2-[[2-[[2-(lH-Indol-3-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl] amino] -2-methyl- 1-propanol, 2-[[2-[( 1 , 1 -Dimethylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-<i]pyrimidin-7- yl]amino]-2-methyl- 1 -propanol, (±)-2-Methyl-2-[[2-[(l-methylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7-yl] amino] - 1 -propanol, (±)-2-Methyl-2-[[2-[(l-methylhexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- d]pyrimidin-7-yl]amino]-l-propanol, 2-[[2-[[(2-Aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl] amino]-2-methyl- 1 -propanol , 2-[[7-[(2-Hydroxy- 1 , 1 -dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- _i]pyrimidin-2-yl]amino]-l,3-propanediol, 2-[[2-[[2-(Ethylthio)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl] amino] -2-methyl- 1 -propanol, (2S)-2-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- <f]pyrimidin-2-yl]amino]-3,3-dimethyl-l-butanol, (αS)-α- [( IR)- 1 - [ [7-[(2-Hydroxy- 1 , 1 -dimethylethyl)amino]-5- [(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-2-yl]amino]-2-methoxyethyl]- benzenemethanol, 2-[[2-(Ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-i Ipyrimidin-7-yl]amino]-2-methyl- 1 -propanol, 2-[[2-[[[3-Fluoro-5-(trifluoromethyl)phenyl]methyl]a ino]-5- [(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]-2-methyl-l-propanol, (±)-2-Methyl-2-[[2-[(l-methylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- cTjpyrimidin-7-ylJamino]- 1 -propanol, 2-[[2-[[(4-Methoxyphenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-<i]pyrimidin- 7-yl]amino]-2-methyl- 1-propanol, 2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]-2-methyl-l-propanol, 2-[[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-cT|pyrimidin- 7-yl]amino]-2-methyl- 1-propanol, 2-[[2-[(Diphenylmethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-< |pyrimidin-7- yl]amino]-2-methyl- 1 -propanol, (2S)-2-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- < i]pyrimidin-2-yl]amino]- 1 -butanol, 2-[[2-[(2,2-Diethoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-rf]pyrimidin-7- yl]amino]-2-methyl- 1 -propanol, 4-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- c?]pyrimidin-2-yl]amino]-l -butanol, ( lS,2S)-2-[[7-[(2-Hydroxy- 1 , 1 -dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ώT]pyrimidin-2-yl]amino]-cyclohexanol, (±)-2-[[2-[(2-Hydroxy-l-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ύf]pyrimidin-7-yl]amino]-2-methyl- 1 -propanol, 2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5--i]pyrimidin- 7-yl]amino]-2-methyl- 1-propanol, (±)-2-[[7-[(2-Hydroxy-l , 1 -dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-2-yl]amino]-l-pentanol, 2-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- < i]pyrimidin-2-yl] amino] -acetamide, (±)-2-[[2-[[l-(4-Fluorophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- . |pyrimidin-7-yl]amino]-2-methyl-propanol, (lR,2S)-2-[[7-[(2-Hydroxy-l,l-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- <i]pyrimidin-2-yl] amino] -cyclohexanol, (αS)-α-[(lR)- l-[[7-[(2-Hydroxy-l , l-dimethylethyl)amino]-5- [(phenylmethyl)thio]thiazolo[4,5-f jpyrimidin-2-yl]amino]ethyl]-benzenemethanol, (±)-2-[[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5--i]pyrimidin-7-yl]amino]-l- propanol, (2R)-4-Methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5- lpyrimidin-7- yl]amino]-l-pentanol, N-[2-(Methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-cf]pyrimidin-7-yl]-L-serine, ethyl ester, (±)-2-[[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5- ( jpyrimidin-7-yl]amino]-l-butanol, (±)-2-[[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5- d] pyrimidin-7-yl] amino] - 1 -propanol, (2R)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[(tetrahydro-2- furanyl)methyl]amino]thiazolo[4,5-rf]pyrimidin-7-yl]amino]-l-pentanol, N-[5-[(Phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5- ]pyrimidin-7-yl]-L-serine, ethyl ester, (±)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]-l-propanol, (±)-4-[2-[[7-[[l-(Hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- d]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide, (±)-4-[2-[[7-[(2-Hydroxy-l-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- <i]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide, 4-[2-[[7-[[( IR)- 1 -(Hydroxymethyl)-3-methylbutyl]amino]-5- [(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-2-yl]amino]ethyl]-benzenesulfonamide, (±)-4-[2-[[7-[(2-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-2- yl]amino]ethyl]-benzenesulfonamide, N 7 -Ethyl-N 2 -[2-(lH-imidazol-4-yl)ethyl]-5-[(ρhenylmethyl)thiothiazolo[4,5-i/]ρyrimidine- 2,7-diamine, N 2 -[2-(lH-Imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]-N 7 -(3-ρyridinylmethyl)- thiazolo[4,5--i]pyrimidine-2,7-diamine, (±)-2-[[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- <i]pyrimidin-7-yl]amino]- 1 -butanol, (±)-2-[[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- <i]pyrimidin-7-yl]amino]- 1-propanol, (2R)-2-[[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ( |pyrimidin-7-yl]amino]-4-methyl-l-pentanol, (±)-l-[[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- <i]pyrimidin-7-yl]amino]-2-propanol, 5-[[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-cTlpyrimidin- 7-yl]amino]- 1 -pentanol, l-[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-i/]pyrimidin- 7-yl]-4-(phenylmethyl)-4-piperidinol, (±)-l-[2-[[2-(lH-Imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- rf]pyrimidin-7-yl]-3-piperidinecarboxamide, 2-[Ethyl[2-[[2-(lH-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- d]pyrimidin-7-yl]amino]-l -ethanol, N 2 -[2-(lH-Imidazol-4-yl)ethyl]-N ^V -dimethyl-5-[(phenylmethyl)thio]- thiazolo[4,5- rf]pyrimidine-2,7-diamine, N 7 -[2-(Diethylamino)ethyl]-N 7 -ethyl-N 2 -[2-(lH-imidazol-4-yl)ethyl]-5- [(phenylmethyl)thio]-thiazolo[4,5-cTIpyrimidine-2,7-diamine, N 2 -(2-Phenoxyethyl)-5-[(phenylmethyl)thio]-N 7 -(3-pyridinylmethyl)-thiazolo[4,5- d]pyrimidine-2,7-diamine, N 2 -(2-Phenoxyethyl)-N 7 -[ 1 -(phenylmethyl)-4-piperidinyl]-5-[(phenylmethyl)thio]- thiazolo[4,5-.i]pyrimidine-2,7-diamine, 2-Methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-<f]pyrimidin- 7-yl] amino] - 1 -propanol, (±)-2-[[2-[(2-Phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-fif]pyrimidin-7- yl]amino]- 1-propanol, (±)-4-Methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- <i]pyrimidin-7-yl] amino] - 1 -pentanol, l-[2-[(2-Phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-ύT]pyrimidin-7-yl]-4- (phenylmethyl)-4-piperidinol, 2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-- |pyrimidin-7-yl]amino]-l- butanol, 2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5--i]pyrimidin-7-yl]amino]-l- propanol, (2R)-2-[[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-J]pyrimidin-7- yl]amino]-4-methyl-l-pentanol, N-[2-(Cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-<i]pyrimidin-7-yl]-L-serine, ethyl ester, (2R)-2-[[2-[[l-(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]-4-methyl- 1 -pentanol, N-[2-[[ 1 -(Hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-<i]pyrimidin-7- yl]-L-serine, ethyl ester, (±)-2-[[7-[Cyclohexyl(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- d]pyrimidin-2-yl] amino]- 1 -pentanol, 2-[2-[[7-(Ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-<f|pyrimidin-2-yl]amino]ethoxy- 1 -ethanol, 2-[2-[[7-[(l-Methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-c pyrimidin-2- yl] amino] ethoxy]- 1 -ethanol, (±)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- < i]pyrimidin-7-yl]amino]- 1 -butanol, 2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-cT]pyrimidin- 7-yl]amino]-2-methyl- 1 -propanol, (2R)-2-[[2-[[2-(2-Hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- c0pyrimidin-7-yl]amino]-4-methyl-l-pentanol, 2-[Cyclohexyl-[2-[[2-(2-hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ύ pyrimidin-7-yl] amino]- 1 -ethanol, (±)-2-[[5-[(Phenylmethyl)thio]-2-(4-piperidinylamino)thiazolo[4,5-flpyrimidin-7- yl]amino]- 1 -propanol, (±)-N-[2-[[7-[[l-(Hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- i ]pyrimidin-2-yl]amino]ethyl]-acetamide, (±)-N-[2-[[7-[(2-Hydroxy-l-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-2-yl]amino]ethyl]-acetamide, N-[2-[[7-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-< ]pyrimidin-2- yl]amino]ethyl]-acetamide, N-[2-[[7-[[(lR)-l-(Hydroxymethyl)-3-methylbutyl]amino]-5- [(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-2-yl]amino]ethyl]-acetamide, N 7 -(2-Methoxyethyl)-5-[(phenylmethyl)thio]-N 2 -[2-(2-thienyl)ethyl]thiazolo[4,5- rf]pyrimidine-2,7-diamine, N 7 -(2-Ethoxyethyl)-5-[(phenylmethyl)thio]-N 2 -[2-(2-thienyl)ethyl]thiazolo[4,5- d]pyrimidine-2,7-diamine, N 7 -(2,2-Dimethylpropyl)-5-[(phenylmethyl)thio]-N 2 -[2-(2-thienyl)ethyl]thiazolo[4,5- ]pyrimidine-2,7-diamine, (2R)-4-Methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5- d]pyrimidin-7-yl]amino]- 1 -pentanol, (±)-l-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-^]pyrimidin-7- yl]amino]- 2-propanol, (±)-2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-^]pyrimidin-7- yl]amino]- 1 -butanol, (±)-2-[[5-[(Phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5- ]pyrimidin-7- yl]amino]- 1 -propanol, (2R)-2-[[2-[(2-Hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5--i]pyrimidin-7- yl]amino]-4-methyl- 1 -pentanol, (±)-N,N-Diethyl-l-[2-[(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7-yl]-3-piperidinecarboxamide, (2R)-2-[[2-[(3-Hydroxypropyl)amino]-5-[( phenylmethyl)thio]thiazolo[4,5-<i]pyrimidin-7- yl]amino]-4-methyl-l -pentanol, (±)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-J]pyrimidin-7- yl]amino]-l-butanol, (±)-2-[[2-[(3-Hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7- yl]amino]- 1-propanol, 2-[[7-[(2-Hydroxy-l-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-6θpyrimidin- 2-yl] amino-acetamide, 4-[l-[7-[(4-Methylcyclohexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-<f]pyrimidin-2- yl]-3-azetidinyl]- 1 -piperazinesulfonamide, 3-[[2-[[2-(4-Moφholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-cT|pyrimidin-7- yl]amino]- 1-propanol, 2-Methyl-2-[[2-[[2-(4-mθφholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- _f]pyrimidin-7-yl]amino]-l-propanol, (±)-2-[[2-[[2-(4-Moφholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- ]pyrimidin-7-yl]amino]- 1 -propanol, (2R)-4-Methyl-2-[[2-[[2-(4-moφholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5- < i]pyrimidin-7-yl] amino]- 1 -pentanol, 2-[[2-(3,4-Dihydroxyphenyl)ethyl]amino]-5-[(phenylmethyl)thio]-thiazolo[4,5- d]pyrimidin-7(4H)-one, (±)-2-[(2-Ηydroxy-l-methylethyl)amino]-5-[(phenylmethyl)thio]-thiazolo[4,5- ]pyrimidin- 7(4H)-one, and their pharmaceutically acceptable salts and solvates. 7. A process for the preparation of a compound of formula (I) as defined in claim 1 which comprises: (a) when X represents -OΗ and R is NΗ 2 , heating a compound of general formula 2 wherein R is as defined in formula (I); or (b) when X represents -OH and R is NH2, reacting a compound of formula 2 1 1 with a compound of general formula (IV), R - L , wherein L represents a leaving group 2 and R is as defined in formula (I); or (c) when X represents -OH or -NR R and R is a hydrogen atom, reacting a corresponding compound of formula (I) in which R is NH2, with a diazotizing agent; or 1 3 4 (d) when X represents -OH and R is a group -NR R , reacting a compound of general formula 2 2 wherein L represents a leaving group and R is as defined in formula (I), with a compound of general formula (VI), R R NH, wherein R 3 and R 4 are as defined in formula (I); or (e) when X represents -NR R and R represents -NR 3 R 4 , reacting a compound of general formula > „3 wherein represents a leaving group and R", R " " and R" are as defined in formula (I), 13„ 1 3 . „ 1 with a compound of gener; 13 144 , . _ 113 144 with a compound of general formula (VHT), NHR R , wherein R and R are as defined in formula (I); or 13 14 1 3 4 ( (ff)) wwhheenn X X rreeppiresents -NR R and R represents -NR R , reacting a compound of general formula wherein L 4 i •s a leaving group, V 5 i-s a leaving group and R ^ is as defined in formula (I), initially with a compound of formula (VI) as defined in (d) above followed by reaction with a compound of formula (VIII) as defined in (e) above; and optionally after (a), (b), (c), (d), (e) or (f) forming a pharmaceutically acceptable salt or solvate of the compound of formula (I). 8. An intermediate compound of formula (V) as defined in claim 7. 9. An intermediate compound of formula VU) as defined in claim 7. 10. An intermediate compound of formula (DC) as defined in claim 7. 11. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6 in association with a pharmaceutically acceptable adjuvant, diluent or carrier. 12. A process for the preparation of a pharmaceutical composition as claimed in claim 1 1 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6 with a pharmaceutically acceptable adjuvant, diluent or carrier. 13. A compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6 for use in therapy. 14. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6 in the manufacture of a medicament for use in therapy. 15. A method o treating a chemokine mediated disease wherein the chemokine binds to a CXCR2 receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6. 16. A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 6. 17. A method according to claim 16, wherein the disease is psoriasis.

Inventors: AUSTIN RUPERT, BAXTER ANDREW, BONNERT ROGER, HUNT FRASER, KINCHIN ELIZABETH, WILLIS PAUL, AUSTIN, RUPERT, BAXTER, ANDREW, BONNERT, ROGER, HUNT, FRASER, KINCHIN, ELIZABETH, WILLIS, PAUL
Applicants: ASTRA AB, ASTRA PHARMA PROD, AUSTIN RUPERT, BAXTER ANDREW, BONNERT ROGER, HUNT FRASER, KINCHIN ELIZABETH, WILLIS PAUL, ASTRA AKTIEBOLAG, ASTRA PHARMACEUTICALS LTD., AUSTIN, RUPERT, BAXTER, ANDREW, BONNERT, ROGER, HUNT, FRASER, KINCHIN, ELIZABETH, WILLIS, PAUL
Application year: 1999
Main classification: C07D513
IPC codes: A61K31, A61P17, A61P29, C07D513